<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004884.pub4" GROUP_ID="ARI" ID="921904021820500036" MERGED_FROM="" MODIFIED="2015-04-08 05:24:01 +0100" MODIFIED_BY="Clare Dooley" REVIEW_NO="A101" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="9.0">
<COVER_SHEET MODIFIED="2015-04-08 05:24:01 +0100" MODIFIED_BY="Clare Dooley">
<TITLE>Antibiotic prophylaxis for preventing meningitis in patients with basilar skull fractures</TITLE>
<CONTACT MODIFIED="2015-04-08 05:24:01 +0100" MODIFIED_BY="Clare Dooley"><PERSON ID="18174" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Bernardo</FIRST_NAME><MIDDLE_INITIALS>O</MIDDLE_INITIALS><LAST_NAME>Ratilal</LAST_NAME><SUFFIX>MD, MSc</SUFFIX><EMAIL_1>bratilal@yahoo.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neurosurgery</DEPARTMENT><ORGANISATION>Hospital de São José</ORGANISATION><ADDRESS_1>Rua José António Serrano</ADDRESS_1><CITY>Lisboa</CITY><ZIP>1150-199</ZIP><COUNTRY CODE="PT">Portugal</COUNTRY><PHONE_1>+351 963047176</PHONE_1><FAX_1>+351 218841052</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2015-04-08 05:24:01 +0100" MODIFIED_BY="Clare Dooley"><PERSON ID="18174" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Bernardo</FIRST_NAME><MIDDLE_INITIALS>O</MIDDLE_INITIALS><LAST_NAME>Ratilal</LAST_NAME><SUFFIX>MD, MSc</SUFFIX><EMAIL_1>bratilal@yahoo.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neurosurgery</DEPARTMENT><ORGANISATION>Hospital de São José</ORGANISATION><ADDRESS_1>Rua José António Serrano</ADDRESS_1><CITY>Lisboa</CITY><ZIP>1150-199</ZIP><COUNTRY CODE="PT">Portugal</COUNTRY><PHONE_1>+351 963047176</PHONE_1><FAX_1>+351 218841052</FAX_1></ADDRESS></PERSON><PERSON ID="FDF5556E82E26AA201D6C2758D661DA8" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>João</FIRST_NAME><LAST_NAME>Costa</LAST_NAME><SUFFIX>MD, PhD</SUFFIX><POSITION>Co-ordinating Editor</POSITION><EMAIL_1>jncosta@medicina.ulisboa.pt</EMAIL_1><ADDRESS><DEPARTMENT>Laboratório de Farmacologia Clínica e Terapêutica</DEPARTMENT><ORGANISATION>Faculdade de Medicina de Lisboa</ORGANISATION><ADDRESS_1>Av. Prof. Egas Moniz</ADDRESS_1><CITY>Lisboa</CITY><ZIP>1649-028</ZIP><COUNTRY CODE="PT">Portugal</COUNTRY><PHONE_1>+351 217802120</PHONE_1><FAX_1>+351 21 7802129</FAX_1></ADDRESS></PERSON><PERSON ID="19846882727092031556101229233908" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Lia</FIRST_NAME><LAST_NAME>Pappamikail</LAST_NAME><EMAIL_1>pappamikail@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neurosurgery</DEPARTMENT><ORGANISATION>Hospital de São José</ORGANISATION><ADDRESS_1>Rua José António Serrano</ADDRESS_1><CITY>Lisboa</CITY><ZIP>1150-199</ZIP><COUNTRY CODE="PT">Portugal</COUNTRY><PHONE_1>+351 96 304 7176</PHONE_1><FAX_1>+351 21 884 1052</FAX_1></ADDRESS></PERSON><PERSON ID="6111" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Cristina</FIRST_NAME><LAST_NAME>Sampaio</LAST_NAME><EMAIL_1>Cristina.Sampaio@chdifoundation.org</EMAIL_1><EMAIL_2>movementdisord@mail.telepac.pt</EMAIL_2><ADDRESS><DEPARTMENT>Laboratório de Farmacologia Clínica e Terapêutica</DEPARTMENT><ORGANISATION>Faculdade de Medicina de Lisboa</ORGANISATION><ADDRESS_1>Hospital de Santa Maria</ADDRESS_1><ADDRESS_2>Av. Prof. Egas Moniz</ADDRESS_2><CITY>Lisboa</CITY><ZIP>1649-028</ZIP><COUNTRY CODE="PT">Portugal</COUNTRY><PHONE_1>+351 21 797 34 53</PHONE_1><FAX_1>+351 21 780 2129</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2014-12-02 10:12:31 +1000" MODIFIED_BY="Liz  Dooley">
<UP_TO_DATE>
<DATE DAY="17" MONTH="6" YEAR="2014"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="17" MONTH="6" YEAR="2014"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="17" MONTH="6" YEAR="2016"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2004"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2006"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2015"/>
</DATES>
<WHATS_NEW MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="17" MONTH="6" YEAR="2014"/>
<DESCRIPTION>
<P>We reran the searches in June 2014. We identified no new trials for inclusion. We excluded six new trials (<LINK REF="STD-Bellamy-2013" TYPE="STUDY">Bellamy 2013</LINK>; <LINK REF="STD-Ibrahim-2012" TYPE="STUDY">Ibrahim 2012</LINK>; <LINK REF="STD-Lauder-2009" TYPE="STUDY">Lauder 2009</LINK>; <LINK REF="STD-Prosser-2011" TYPE="STUDY">Prosser 2011</LINK>; <LINK REF="STD-Sherif-2012" TYPE="STUDY">Sherif 2012</LINK>; <LINK REF="STD-Zix-2013" TYPE="STUDY">Zix 2013</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2014-12-02 10:12:57 +1000" MODIFIED_BY="Liz  Dooley">
<DATE DAY="17" MONTH="6" YEAR="2014"/>
<DESCRIPTION>
<P>Our conclusions remain unchanged.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2014-11-27 11:38:31 +1000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-11-27 11:38:31 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="17" MONTH="2" YEAR="2011"/>
<DESCRIPTION>
<P>Searches conducted. No new trials were included or excluded in this update.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2014-11-27 11:38:26 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="10" MONTH="1" YEAR="2011"/>
<DESCRIPTION>
<P>A new author joined the review team to update this review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-10-27 16:27:43 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="26" MONTH="7" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2011-03-17 15:59:29 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="25" MONTH="9" YEAR="2005"/>
<DESCRIPTION>
<P>Searches conducted.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Clinical Therapeutics Institute, Lisbon Faculty of Medicine</NAME>
<COUNTRY CODE="PT">Portugal</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Centro Cochrane Iberoamericano</NAME>
<COUNTRY CODE="ES">Spain</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2015-04-06 19:36:30 +1000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2015-04-06 17:10:21 +1000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2011-04-19 17:43:11 +1000" MODIFIED_BY="[Empty name]">Antibiotics to prevent infection of the brain coverings (meningitis) in patients with basilar skull fracture</TITLE>
<SUMMARY_BODY MODIFIED="2015-04-06 17:10:21 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Review question</B>
</P>
<P>Is it beneficial for patients with basilar skull fractures to receive a course of intravenous antibiotics?</P>
<P>
<B>Background</B>
</P>
<P>Basilar skull fracture (7% to 15.8% of all skull fractures) places the central nervous system in contact with bacteria from the nose and throat and may be associated with cerebrospinal fluid leakage (occurring in 2% to 20.8% of patients). Blood or watery discharge from the nose or ears, bruising behind the ear or around the eyes, hearing loss, inability to perceive odours or facial asymmetry may lead physicians to the diagnosis of basilar skull fracture. Patients with a basilar skull fracture may develop meningitis and some doctors give antibiotics in an attempt to reduce this risk.</P>
<P>
<B>Study characteristics</B>
</P>
<P>This review examined five randomised controlled trials, comprising a total of 208 participants with basilar skull fracture, which compared those who received preventive antibiotic therapy with those who did not receive antibiotics, to establish how many participants developed meningitis. The evidence is current to June 2014.</P>
<P>
<B>Key results</B>
</P>
<P>The available data did not support the use of prophylactic antibiotics, as there is no proven benefit of such therapy. There was a possible adverse effect of increased susceptibility to infection with more pathogenic (disease-causing) organisms. We suggest that research is needed to address this question, as there are too few studies available on this subject and they have overall design shortcomings and small combined numbers of participants studied.</P>
<P>
<B>Quality of the evidence</B>
</P>
<P>We ranked the evidence as being of moderate quality because it is based on randomised data, although with some methodological limitations in design that caused us to downgrade the quality of the trials.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2015-04-06 19:23:54 +1000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]">
<P>Basilar skull fractures predispose patients to meningitis because of the possible direct contact of bacteria in the paranasal sinuses, nasopharynx or middle ear with the central nervous system (CNS). Cerebrospinal fluid (CSF) leakage has been associated with a greater risk of contracting meningitis. Antibiotics are often given prophylactically, although their role in preventing bacterial meningitis has not been established.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]">
<P>To evaluate the effectiveness of prophylactic antibiotics for preventing meningitis in patients with basilar skull fractures.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]">
<P>We searched CENTRAL (2014, Issue 5), MEDLINE (1966 to June week 1, 2014), EMBASE (1974 to June 2014) and LILACS (1982 to June 2014). We also performed an electronic search of meeting proceedings from the American Association of Neurological Surgeons (1997 to September 2005) and handsearched the abstracts of meeting proceedings of the European Association of Neurosurgical Societies (1995, 1999 and 2003).</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials (RCTs) comparing any antibiotic versus placebo or no intervention. We also identified non-RCTs to perform a separate meta-analysis in order to compare results.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2015-04-06 17:04:25 +1000" MODIFIED_BY="[Empty name]">
<P>Three review authors independently screened and selected trials, assessed risk of bias and extracted data. We sought clarification with trial authors when needed. We pooled risk ratios (RRs) for dichotomous data with their 95% confidence intervals (CIs) using a random-effects model. We assessed the overall quality of evidence using the GRADE (Grades of Recommendation, Assessment, Development and Evaluation) approach.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2015-04-06 19:23:54 +1000" MODIFIED_BY="[Empty name]">
<P>In this update we did not identify any new trials for inclusion. We included five RCTs with 208 participants in the review and meta-analysis. We also identified 17 non-RCTs comparing different types of antibiotic prophylaxis with placebo or no intervention in patients with basilar skull fractures. Most trials presented insufficient methodological detail. All studies included meningitis in their primary outcome. When we evaluated the five included RCTs, there were no significant differences between antibiotic prophylaxis groups and control groups in terms of reduction of the frequency of meningitis, all-cause mortality, meningitis-related mortality and need for surgical correction in patients with CSF leakage. There were no reported adverse effects of antibiotic administration, although one of the five RCTs reported an induced change in the posterior nasopharyngeal flora towards potentially more pathogenic organisms resistant to the antibiotic regimen used in prophylaxis. We performed a subgroup analysis to evaluate the primary outcome in patients with and without CSF leakage. We also completed a meta-analysis of all the identified controlled non-RCTs (enrolling a total of 2168 patients), which produced results consistent with the randomised data from the included studies.</P>
<P>Using the GRADE approach, we assessed the quality of trials as moderate.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]">
<P>Currently available evidence from RCTs does not support prophylactic antibiotic use in patients with basilar skull fractures, whether there is evidence of CSF leakage or not. Until more research is available, the effectiveness of antibiotics in patients with basilar skull fractures cannot be determined because studies published to date are flawed by biases. Large, appropriately designed RCTs are needed.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2015-04-06 19:36:30 +1000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]">
<P>The estimated incidence of basilar skull fracture from non-penetrating head trauma varies between 7% and 15.8% of all skull fractures, with associated cerebrospinal fluid (CSF) leakage occurring in 2% to 20.8% of patients (<LINK REF="REF-Buchanan-2004" TYPE="REFERENCE">Buchanan 2004</LINK>). Clinical signs that may lead a physician to suspect a basilar skull fracture include CSF otorrhoea or rhinorrhoea, bilateral periorbital ecchymosis, Battle's sign, peripheral facial nerve palsy, haemotympanum or tympanic membrane perforation with blood in the external auditory canal, hearing loss, evidence of vestibular dysfunction and anosmia. High-resolution bone computed tomographic (CT) scans have dramatically improved the radiological diagnosis of this type of fracture. Basilar skull fractures are of special significance because the dura mater may be torn adjacent to the fracture site, placing the central nervous system (CNS) in contact with bacteria from the paranasal sinuses, nasopharynx or middle ear. If the dura mater is torn, CSF leakage could occur. Basilar skull fractures will predispose the patient to meningitis. A greater associated risk has been reported when CSF leakage exists, in particular if it persists for more than seven days (<LINK REF="REF-Leech-1973" TYPE="REFERENCE">Leech 1973</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]">
<P>The role of prophylactic antibiotics for preventing bacterial meningitis in patients with basilar skull fractures is controversial. Growing concern about the emergence of resistant organisms argues against their use. In addition, there are reports of a higher incidence of meningitis in patients with basilar skull fractures who have received prophylactic antibiotics (<LINK REF="STD-Choi-1996" TYPE="STUDY">Choi 1996</LINK>).<BR/>
</P>
</INTERVENTION>
<THEORY MODIFIED="2009-10-17 18:47:08 +1000" MODIFIED_BY="[Empty name]">
<P>Chemoprophylaxis with antibiotics in basilar skull fractures may reduce the incidence of meningitis. </P>
</THEORY>
<IMPORTANCE MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]">
<P>A meta-analysis showed a statistically significant reduction in the incidence of meningitis with prophylactic antibiotic therapy for patients with post-traumatic CSF leakage (<LINK REF="REF-Brodie-1997" TYPE="REFERENCE">Brodie 1997</LINK>). Another meta-analysis concluded that antibiotic prophylaxis after a basilar skull fracture does not appear to decrease the risk of meningitis, independent of whether or not CSF leakage has occurred (<LINK REF="REF-Villalobos-1998" TYPE="REFERENCE">Villalobos 1998</LINK>). These studies did not include an extensive review of the literature; both searched papers only until 1995 and 1996 respectively, and their conclusions were based mainly on retrospective and observational studies.</P>
<P>The inadequacies of these reviews and their conflicting conclusions led us to decide to search for and analyse evidence for the use of prophylactic antibiotics for preventing bacterial meningitis in patients with a basilar skull fracture.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]">
<P>To evaluate the effectiveness of prophylactic antibiotics for preventing meningitis in patients with basilar skull fractures.<BR/>
</P>
</OBJECTIVES>
<METHODS MODIFIED="2015-04-06 19:36:30 +1000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2015-02-26 19:58:39 +1000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials (RCTs) comparing any antibiotic versus placebo or no intervention. We also identified non-RCTs to perform a separate meta-analysis in order to compare results.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]">
<P>Patients of any age with a recent basilar skull fracture, independent of the presence and severity of CSF leakage.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2015-02-26 19:58:39 +1000" MODIFIED_BY="[Empty name]">
<P>Any antibiotic administered at the time of primary treatment of the basilar skull fracture compared with placebo or no antibiotic. We excluded trials comparing different antibiotics, different antibiotic dosages, different routes of administration, or differences in the timing or duration of administration.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2014-12-02 11:20:38 +1000" MODIFIED_BY="Liz  Dooley">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2014-12-02 11:20:38 +1000" MODIFIED_BY="Liz  Dooley">
<OL>
<LI>Frequency of meningitis: suspected clinically (fever, neck stiffness, deterioration of neurological status, headache) and confirmed by lumbar puncture (CSF analysis including biochemistry, Gram stains or bacteriological cultures (or both)).</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2011-04-19 17:53:53 +1000" MODIFIED_BY="[Empty name]">
<OL>
<LI>All-cause mortality/meningitis-related mortality.</LI>
<LI>Need for surgical correction in patients with CSF leakage.</LI>
<LI>Non-CNS infection.</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2015-04-06 17:28:03 +1000" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]">
<P>For this update, we searched the Cochrane Central Register of Controlled Trials (CENTRAL 2014, Issue 5) (accessed 18 June 2014), which contains the Cochrane Acute Respiratory Infections (ARI) Group's Specialised Register, MEDLINE (January 2011 to June week 1, 2014), EMBASE (January 2011 to June 2014) and LILACS (2011 to June 2014). Previous searches are described in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
<P>We used the search strategy described in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK> to search MEDLINE and CENTRAL. We used no filter for the MEDLINE search as we wished to identify both randomised and non-randomised studies and the number of search results was manageable without a filter. We adapted the search strategy for EMBASE (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>) and LILACS (<LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>). We applied no language or publication restrictions.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2015-04-06 17:28:03 +1000" MODIFIED_BY="[Empty name]">
<P>We searched the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) and ClinicalTrials.gov for completed and ongoing trials (27 June 2014). We screened titles, keywords and abstracts of the citations downloaded from the electronic searches and obtained full copies of reports of potentially suitable trials for further assessment. The search strategy also included a search of the reference lists of identified trials and basilar skull fracture review articles, and personal communication with other researchers in the field. We handsearched abstracts of meeting proceedings from the European Association of Neurosurgical Societies (1995, 1999 and 2003). We were unable to search the latter source in this 2014 update (see <LINK TAG="PRO_REV_DIFF" TYPE="SECTION">Differences between protocol and review</LINK>).</P>
<P>We contacted researchers active in the field, for information regarding unpublished trials. We also contacted authors of published trials for further information and unpublished data. We did not apply any language restrictions.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2015-04-06 19:36:30 +1000" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2011-04-19 17:57:34 +1000" MODIFIED_BY="[Empty name]">
<P>Three review authors (BR, JC, LP) independently assessed the studies identified by the search strategy, to identify potentially suitable trials for the review according to the criteria outlined above. We resolved disagreements by discussion with the fourth author (CS).</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]">
<P>Three authors (BR, JC, LP) independently assessed the full papers for type of participants, type and dose of antibiotic used, methodological quality, number of patients excluded or lost to follow-up and the outcome measures stated in the protocol. We recorded extracted data on a data collection form. We resolved disagreements by discussion.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]">
<P>We investigated sources of bias. Two authors (LP, BR) independently assessed the global quality of included trials using the 'Risk of bias' assessment tool, as outlined in the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We resolved disagreements by discussion.</P>
</QUALITY_ASSESSMENT>
<UNIT_OF_ANALYSIS MODIFIED="2014-12-02 10:43:22 +1000" MODIFIED_BY="Liz  Dooley">
<P>We performed statistical analysis using Review Manager software (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>). We calculated the significance of any differences between ORs using a standard method (<LINK REF="REF-Egger-2001" TYPE="REFERENCE">Egger 2001</LINK>).</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2011-04-19 18:09:08 +1000" MODIFIED_BY="[Empty name]">
<P>We contacted the original trial authors whenever relevant missing data were detected.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2015-04-06 17:41:16 +1000" MODIFIED_BY="[Empty name]">
<P>We performed statistical analyses using the statistical software provided by the Cochrane Collaboration (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>). We investigated statistical heterogeneity between trial results using the I<SUP>2</SUP> statistic (<LINK REF="REF-Higgins-2002" TYPE="REFERENCE">Higgins 2002</LINK>).</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2011-04-19 18:16:42 +1000" MODIFIED_BY="[Empty name]">
<P>We would have assessed publication bias according to the recommendations on testing for funnel plot asymmetry if there had been sufficient numbers of trials (more than 10) in any meta-analysis (<LINK REF="REF-Sterne-2011" TYPE="REFERENCE">Sterne 2011</LINK>). We would have examined possible causes if asymmetry had been identified.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2015-04-06 17:12:11 +1000" MODIFIED_BY="[Empty name]">
<P>We reported the results of meta-analysis as odds ratios (ORs) and 95% confidence intervals (CIs) for dichotomous outcomes.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2011-04-19 18:17:30 +1000" MODIFIED_BY="[Empty name]">
<P>We previously planned to investigate heterogeneity by undertaking a subgroup analysis of patients with or without CSF leakage in the event of uncovering significant heterogeneity.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2015-04-06 19:36:30 +1000" MODIFIED_BY="[Empty name]">
<P>We performed a meta-analysis of all the controlled, non-randomised studies identified in order to evaluate the consistency of the results of the main meta-analysis.</P>
<SUBSECTION>
<HEADING LEVEL="3">Summarising and interpreting results</HEADING>
<P>We used the GRADE (Grades of Recommendation, Assessment, Development and Evaluation) approach to interpret findings (<LINK REF="REF-Sch_x00fc_nemann-2011" TYPE="REFERENCE">Schünemann 2011</LINK>) and used GRADE profiler (<LINK REF="REF-GRADEpro-2014" TYPE="REFERENCE">GRADEpro 2014</LINK>) to import data from <LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK> to create <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>. This table provides information on the quality of evidence from studies, the magnitude of effects of the interventions examined, and the sum of available data on all important outcomes from each study included in the comparison. The GRADE approach (<LINK REF="REF-Sch_x00fc_nemann-2011" TYPE="REFERENCE">Schünemann 2011</LINK>) considers 'quality' to be a judgement of the extent to which we can be confident that the estimates of effect are correct. We downgraded evidence from randomised controlled studies that was initially graded as 'high quality', by one or two levels on each of five domains after full consideration of any limitations in the design of the studies, indirectness (or applicability) of the evidence, inconsistency, imprecision of the effect estimates, and the possibility of publication bias. </P>
<P>A GRADE quality level of 'high' reflects confidence that the true effect lies close to the estimate of the effect of a given outcome. A judgement of 'moderate' quality indicates that the true effect is likely to be close to the estimate of the effect, but acknowledges that it could be substantially different. Evidence of 'low' and 'very low' quality limits our confidence in the effect estimate (<LINK REF="REF-Balshem-2011" TYPE="REFERENCE">Balshem 2011</LINK>).</P>
<P>We selected the following outcomes for <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>.</P>
<OL>
<LI>Frequency of meningitis.</LI>
<LI>All-cause mortality.</LI>
<LI>Meningitis-related mortality.</LI>
<LI>Need for surgical correction of CSF leakage.</LI>
<LI>Non-CNS infection.</LI>
</OL>
</SUBSECTION>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2015-04-06 18:20:23 +1000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2015-03-27 07:45:38 +1000" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2015-03-27 07:45:38 +1000" MODIFIED_BY="[Empty name]">
<P>In this 2014 update we retrieved a total of 794 records. The 2011 update retrieved a total of 168 new records (when duplicates were removed from searches of MEDLINE (28 records), EMBASE (118 records), CENTRAL (14 records) and LILACS (eight records)) (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). This 2014 update yielded the addition of six new excluded studies.</P>
<P>This review identified five RCTs comparing prophylactic antibiotics in basilar skull fracture with placebo or no antibiotics (<LINK REF="STD-Demetriades-1992" TYPE="STUDY">Demetriades 1992</LINK>; <LINK REF="STD-Eftekhar-2004" TYPE="STUDY">Eftekhar 2004</LINK>; <LINK REF="STD-Hoff-1976" TYPE="STUDY">Hoff 1976</LINK>; <LINK REF="STD-Ignelzi-1975a" TYPE="STUDY">Ignelzi 1975a</LINK>; <LINK REF="STD-Klastersky-1976" TYPE="STUDY">Klastersky 1976</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2015-03-27 07:45:36 +1000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Meningitis in patients with basilar skull fractures</HEADING>
<P>We found five RCTs with available data comparing prophylactic antibiotics in basilar skull fractures with placebo or no antibiotics (<LINK REF="STD-Demetriades-1992" TYPE="STUDY">Demetriades 1992</LINK>; <LINK REF="STD-Eftekhar-2004" TYPE="STUDY">Eftekhar 2004</LINK>; <LINK REF="STD-Hoff-1976" TYPE="STUDY">Hoff 1976</LINK>; <LINK REF="STD-Ignelzi-1975a" TYPE="STUDY">Ignelzi 1975a</LINK>; <LINK REF="STD-Klastersky-1976" TYPE="STUDY">Klastersky 1976</LINK>) (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>). All these studies were single-centre, conducted in South Africa, Iran, USA or Belgium, and were published between 1975 and 2004. All had a parallel design and were stated by the trial authors to be randomised, although the method of randomisation was not clearly described in any trial report.</P>
<P>All trials included participants with a clinical or radiological diagnosis of basilar skull fracture. Entry criteria did not differ considerably. Exceptions were the <LINK REF="STD-Hoff-1976" TYPE="STUDY">Hoff 1976</LINK> trial, in which CSF leakage was an exclusion criterion, and the <LINK REF="STD-Klastersky-1976" TYPE="STUDY">Klastersky 1976</LINK> trial, in which the participants had to have evidence of CSF leakage to be included.</P>
<P>The primary outcome for all trials included the occurrence of meningitis. In three trials the primary outcome was a composite outcome that also included extracranial infection (wound sepsis, pneumonia, urinary tract infection), bacterial colonisation of bronchial secretions or urine, change in the posterior nasopharyngeal flora, or death from brain damage (<LINK REF="STD-Demetriades-1992" TYPE="STUDY">Demetriades 1992</LINK>; <LINK REF="STD-Ignelzi-1975a" TYPE="STUDY">Ignelzi 1975a</LINK>; <LINK REF="STD-Klastersky-1976" TYPE="STUDY">Klastersky 1976</LINK>). Criteria for these diagnoses were based on clinical grounds and further investigations and prophylactic medication were commenced as soon as the diagnosis of basilar skull fracture was made in all trials. None of the studies reported data on outcomes of safety and tolerability of prophylactic antibiotics.</P>
<P>
<LINK REF="STD-Ignelzi-1975a" TYPE="STUDY">Ignelzi 1975a</LINK> performed a small controlled trial with 10 participants with basilar skull fractures that was included in a report of a larger retrospective study. The presence of CSF fistulae in these participants was not described and the participants were randomised to one group that received prophylactic ampicillin or cephalothin 1 g six-hourly for 10 days or another group that did not. The <LINK REF="STD-Klastersky-1976" TYPE="STUDY">Klastersky 1976</LINK> study performed a double-blind controlled trial that enrolled 52 participants and compared five mega units of penicillin G given intravenously six-hourly for a mean duration of 7.7 days; the placebo was given under identical conditions.</P>
<P>
<LINK REF="STD-Hoff-1976" TYPE="STUDY">Hoff 1976</LINK> enrolled 160 participants assigned randomly and blindly to one of three groups: no antibiotic (group 1), 1.2 million units of intravenous penicillin daily for three days (group 2), or 20 million units of intravenous penicillin daily for three days (group 3). No cases of meningitis were found but the numbers of participants enrolled in each group were not provided. Although we have contacted the trial author, further information was no longer available.</P>
<P>
<LINK REF="STD-Demetriades-1992" TYPE="STUDY">Demetriades 1992</LINK> randomised 37 participants to three groups: no antibiotic (group A), 1 g intravenous ceftriaxone daily for three days (group B), or combined ampicillin (1 g intravenous six-hourly)/sulphadiazine (0.5 g intravenous six-hourly) (group C).</P>
<P>
<LINK REF="STD-Eftekhar-2004" TYPE="STUDY">Eftekhar 2004</LINK> studied 109 participants with acute traumatic pneumocephalus verified by a CT scan, who were followed until occurrence of meningitis or at least for five days post-trauma. They randomised the participants to one of two groups: the prophylactic antibiotic treatment given (PAT+) group, in which ceftriaxone was administered at a dose of 1 g twice a day for five days; and the prophylactic antibiotic treatment not given (PAT-) group, in which ceftriaxone was not administered.</P>
<P>Overall, 368 participants were enrolled in these five studies. Two of them enrolled 73% of these participants (<LINK REF="STD-Eftekhar-2004" TYPE="STUDY">Eftekhar 2004</LINK>; <LINK REF="STD-Hoff-1976" TYPE="STUDY">Hoff 1976</LINK>). Since we could not access the number of participants included in each group of the <LINK REF="STD-Hoff-1976" TYPE="STUDY">Hoff 1976</LINK> trial, we could not include it in the meta-analysis. We therefore analysed a total of 208 participants from four RCTs: 109 participants in the treatment group and 99 in the control group.</P>
<P>In three trials participants were well matched between the treatment and control arms for demographics, clinical status at admission and presence of rhinorrhoea or otorrhoea (<LINK REF="STD-Demetriades-1992" TYPE="STUDY">Demetriades 1992</LINK>; <LINK REF="STD-Eftekhar-2004" TYPE="STUDY">Eftekhar 2004</LINK>; <LINK REF="STD-Klastersky-1976" TYPE="STUDY">Klastersky 1976</LINK>). The other trials did not describe the characteristics of the population included in each group (<LINK REF="STD-Hoff-1976" TYPE="STUDY">Hoff 1976</LINK>; <LINK REF="STD-Ignelzi-1975a" TYPE="STUDY">Ignelzi 1975a</LINK>).</P>
<P>Two studies provided sufficient descriptions for withdrawals and dropouts to determine the number of participants in each treatment group entering and completing the trial (<LINK REF="STD-Demetriades-1992" TYPE="STUDY">Demetriades 1992</LINK>; <LINK REF="STD-Klastersky-1976" TYPE="STUDY">Klastersky 1976</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Meningitis in participants with basilar skull fracture concerning the presence of CSF leakage</HEADING>
<P>There was only one study in which the presence of CSF leakage was not specified (<LINK REF="STD-Ignelzi-1975a" TYPE="STUDY">Ignelzi 1975a</LINK>). CSF leakage was an exclusion criteria in the <LINK REF="STD-Hoff-1976" TYPE="STUDY">Hoff 1976</LINK> study. Traumatic rhinorrhoea or otorrhoea had to be present in the participants included in the <LINK REF="STD-Klastersky-1976" TYPE="STUDY">Klastersky 1976</LINK> study. The other two trials included participants with and without CSF leakage (<LINK REF="STD-Demetriades-1992" TYPE="STUDY">Demetriades 1992</LINK>; <LINK REF="STD-Eftekhar-2004" TYPE="STUDY">Eftekhar 2004</LINK>).</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]">
<P>The <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table contains all studies that have been systematically reviewed. We excluded 23 studies. Of these, 15 were retrospective controlled studies (<LINK REF="STD-Ash-1992" TYPE="STUDY">Ash 1992</LINK>; <LINK REF="STD-Choi-1996" TYPE="STUDY">Choi 1996</LINK>; <LINK REF="STD-Clemenza-1995" TYPE="STUDY">Clemenza 1995</LINK>; <LINK REF="STD-Dagi-1983" TYPE="STUDY">Dagi 1983</LINK>; <LINK REF="STD-Einhorn-1978" TYPE="STUDY">Einhorn 1978</LINK>; <LINK REF="STD-Eljamel-1993" TYPE="STUDY">Eljamel 1993</LINK>; <LINK REF="STD-Frazee-1988" TYPE="STUDY">Frazee 1988</LINK>; <LINK REF="STD-Friedman-2001" TYPE="STUDY">Friedman 2001</LINK>; <LINK REF="STD-Helling-1988" TYPE="STUDY">Helling 1988</LINK>; <LINK REF="STD-MacGee-1970" TYPE="STUDY">MacGee 1970</LINK>; <LINK REF="STD-McGuirt-1995" TYPE="STUDY">McGuirt 1995</LINK>; <LINK REF="STD-Raskind-1965" TYPE="STUDY">Raskind 1965</LINK>; <LINK REF="STD-Steidtmann-1997" TYPE="STUDY">Steidtmann 1997</LINK>; <LINK REF="STD-Tos-1973" TYPE="STUDY">Tos 1973</LINK>; <LINK REF="STD-Zrebeet-1986" TYPE="STUDY">Zrebeet 1986</LINK>), four were prospective observational studies with an historical control group (<LINK REF="STD-Gonzalez-1998" TYPE="STUDY">Gonzalez 1998</LINK>; <LINK REF="STD-Ibrahim-2012" TYPE="STUDY">Ibrahim 2012</LINK>; <LINK REF="STD-Ignelzi-1975b" TYPE="STUDY">Ignelzi 1975b</LINK>; <LINK REF="STD-Lauder-2009" TYPE="STUDY">Lauder 2009</LINK>), three were author statements and opinion (<LINK REF="STD-Bellamy-2013" TYPE="STUDY">Bellamy 2013</LINK>; <LINK REF="STD-Prosser-2011" TYPE="STUDY">Prosser 2011</LINK>; <LINK REF="STD-Sherif-2012" TYPE="STUDY">Sherif 2012</LINK>), and one was a randomised controlled trial with both groups receiving antibiotics for orbital blow-out fractures (<LINK REF="STD-Zix-2013" TYPE="STUDY">Zix 2013</LINK>). There was no specification about the presence of CSF leakage in seven of these studies (<LINK REF="STD-Ash-1992" TYPE="STUDY">Ash 1992</LINK>; <LINK REF="STD-Gonzalez-1998" TYPE="STUDY">Gonzalez 1998</LINK>; <LINK REF="STD-Helling-1988" TYPE="STUDY">Helling 1988</LINK>; <LINK REF="STD-Ignelzi-1975b" TYPE="STUDY">Ignelzi 1975b</LINK>; <LINK REF="STD-Lauder-2009" TYPE="STUDY">Lauder 2009</LINK>; <LINK REF="STD-Prosser-2011" TYPE="STUDY">Prosser 2011</LINK>; <LINK REF="STD-Tos-1973" TYPE="STUDY">Tos 1973</LINK>). Eight included only participants with CSF leakage, either otorrhoea or rhinorrhoea (<LINK REF="STD-Clemenza-1995" TYPE="STUDY">Clemenza 1995</LINK>; <LINK REF="STD-Eljamel-1993" TYPE="STUDY">Eljamel 1993</LINK>; <LINK REF="STD-Friedman-2001" TYPE="STUDY">Friedman 2001</LINK>; <LINK REF="STD-Ibrahim-2012" TYPE="STUDY">Ibrahim 2012</LINK>; <LINK REF="STD-MacGee-1970" TYPE="STUDY">MacGee 1970</LINK>; <LINK REF="STD-McGuirt-1995" TYPE="STUDY">McGuirt 1995</LINK>; <LINK REF="STD-Raskind-1965" TYPE="STUDY">Raskind 1965</LINK>; <LINK REF="STD-Sherif-2012" TYPE="STUDY">Sherif 2012</LINK>), and one excluded participants with CSF leak (<LINK REF="STD-Zix-2013" TYPE="STUDY">Zix 2013</LINK>).</P>
<P>The remaining six studies included participants with or without CSF leakage (<LINK REF="STD-Choi-1996" TYPE="STUDY">Choi 1996</LINK>; <LINK REF="STD-Dagi-1983" TYPE="STUDY">Dagi 1983</LINK>; <LINK REF="STD-Einhorn-1978" TYPE="STUDY">Einhorn 1978</LINK>; <LINK REF="STD-Frazee-1988" TYPE="STUDY">Frazee 1988</LINK>; <LINK REF="STD-Steidtmann-1997" TYPE="STUDY">Steidtmann 1997</LINK>; <LINK REF="STD-Zrebeet-1986" TYPE="STUDY">Zrebeet 1986</LINK>). Overall, 2168 participants were included in these 17 studies, in which 1141 participants were treated with antibiotics and 1027 participants were not.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]">
<P>The overall risk of bias is presented graphically in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and summarised in <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>. (See <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>).</P>
<ALLOCATION MODIFIED="2011-05-19 21:13:35 +1000" MODIFIED_BY="[Empty name]">
<P>All studies stated that patients were randomised between the treatment and control groups. The precise method of randomisation and details of concealment of allocation were not explained in any trial. We considered the method of allocation to be unclear in all trials.<BR/>
</P>
</ALLOCATION>
<BLINDING MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]">
<P>Only one study was double-blinded throughout, using interventions of identical appearance (antibiotics or placebo) (<LINK REF="STD-Klastersky-1976" TYPE="STUDY">Klastersky 1976</LINK>). The other studies were not placebo-controlled and did not measure outcomes blindly. In addition, only two studies reported the number of and reasons for patients leaving the trials (<LINK REF="STD-Demetriades-1992" TYPE="STUDY">Demetriades 1992</LINK>; <LINK REF="STD-Klastersky-1976" TYPE="STUDY">Klastersky 1976</LINK>).</P>
<P>Data were analysed on a per-protocol basis in all trials.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]">
<P>Missing data precluded several planned analyses in this systematic review. We were able partly to overcome this problem because we had access to further data from the original trial of Eftekhar (<LINK REF="STD-Eftekhar-2004" TYPE="STUDY">Eftekhar 2004</LINK>), kindly provided by the author himself. We sought further information for some of the other studies, but without success. As previously stated, the number of patients in each group was not accessible in the <LINK REF="STD-Hoff-1976" TYPE="STUDY">Hoff 1976</LINK> study; although none of the 160 patients enrolled had meningitis, we could not include this trial in the meta-analysis.</P>
</EXCLUSIONS>
<OTHER_BIAS_SOURCES MODIFIED="2011-05-19 21:14:30 +1000" MODIFIED_BY="[Empty name]">
<P>We identified no other potential sources of bias.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2015-04-06 18:20:23 +1000" MODIFIED_BY="[Empty name]">
<P>We were able to perform a meta-analysis with five of the randomised controlled trials (RCTs) included in this review. Since we primarily aimed to compare prophylactic antibiotics with no antibiotic or placebo in patients with basilar skull fractures and to identify the influence of cerebrospinal fluid (CSF) leakage on the frequency of meningitis in these patients, we performed a subgroup analysis of patients with and without CSF leakage. We tested statistical heterogeneity between trial results using the I<SUP>2</SUP> statistic and found no evidence of heterogeneity in any of the outcomes measured (I<SUP>2 </SUP>statistic = 0%).</P>
<P>The efficacy outcomes did not show significant differences between treatment and control groups in any of the included trials, when considering either the total population or the subgroup of patients with CSF leakage. (See <LINK TAG="SUMMARY_OF_RESULTS" TYPE="SECTION">Summary of main results</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Primary outcome</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">1. Frequency of meningitis</HEADING>
<P>We found no significant differences for this outcome (odds ratio (OR) 0.69; 95% confidence interval (CI) 0.29 to 1.61) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). In addition, we found no differences in the subgroups of patients with CSF leakage (OR 0.44; 95% CI 0.09 to 2.15) or without CSF leakage (OR 0.77; 95% CI 0.25 to 2.41) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK> - 1.1.1 and 1.1.2). Using GRADE, we graded the evidence as being of moderate quality since there was potential selection and detection bias in two of the four RCTs as well as unclear risk of reporting bias in one study (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">1. All-cause mortality/meningitis-related mortality</HEADING>
<P>We accessed relevant data from the five trials. We found no significant differences for all-cause mortality (OR 1.68; 95% CI 0.41 to 6.95) (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>) or for meningitis-related mortality (OR 1.03; 95% CI 0.14 to 7.40) (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>). We rated the evidence using GRADE as moderate quality, since there was potential selection and detection bias in two of the four RCTs as well as unclear risk of reporting bias in one study (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Need for surgical correction in patients with CSF leakage</HEADING>
<P>Only one study provided data for this secondary outcome and no participants in either treatment or control groups underwent surgical correction for CSF leakage in this trial (<LINK REF="STD-Eftekhar-2004" TYPE="STUDY">Eftekhar 2004</LINK>) (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>). We rated the quality of evidence as low quality according to GRADE, since it pertained to a single study with potential detection bias (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Non-central nervous system (CNS) infection</HEADING>
<P>Only one study provided data for this outcome (<LINK REF="STD-Klastersky-1976" TYPE="STUDY">Klastersky 1976</LINK>). No significant differences were found (OR 0.61; 95% CI 0.15 to 2.46) (<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>). We rated the evidence as high quality, since although extracted from a single RCT, there was little risk of bias and few concerns raised regarding inconsistency, indirectness or imprecision (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Meta-analysis of controlled non-randomised studies identified</HEADING>
<P>In order to study the consistency of these results we performed a meta-analysis of all the controlled non-randomised studies identified and previously described in the <LINK TAG="EXCLUDED_STUDIES_DESCR" TYPE="SECTION">Excluded studies</LINK> section. Globally, these studies enrolled 2168 participants (treatment group 1141; control group 1027). Tests for heterogeneity were not statistically significant (Chi<SUP>2</SUP> test, P value = 0.16; I<SUP>2</SUP> statistic = 26%). Globally, the frequency of meningitis in the treatment group was 6.92% and in the control group 6.52% (P value = 0.65) (random-effects model OR 1.13; 95% CI 0.67 to 1.88). Individually, only one study showed a significant difference favouring the treatment group (OR 0.47; 95% CI 0.25 to 0.88) (<LINK REF="STD-Eljamel-1993" TYPE="STUDY">Eljamel 1993</LINK>). This study contributed most to the results (weight 19.4%), but it did not impact significantly on the direction of the results. Additionally, we performed a subgroup analysis for patients with CSF leakage (529 participants in the treatment group and 260 in the control group) and without CSF leakage (334 participants in the treatment group and 292 in the control group). In five studies the presence of CSF leakage was not specified (278 participants in treatment groups and 475 in control groups) (<LINK REF="STD-Ash-1992" TYPE="STUDY">Ash 1992</LINK>; <LINK REF="STD-Gonzalez-1998" TYPE="STUDY">Gonzalez 1998</LINK>; <LINK REF="STD-Helling-1988" TYPE="STUDY">Helling 1988</LINK>; <LINK REF="STD-Ignelzi-1975b" TYPE="STUDY">Ignelzi 1975b</LINK>; <LINK REF="STD-Tos-1973" TYPE="STUDY">Tos 1973</LINK>). The OR (random-effects model) for participants with CSF leakage was 0.61 (95% CI 0.37 to 0.99) and for patients without CSF leakage it was 0.86 (95% CI 0.27 to 2.78). In the subgroup of patients for which no data were available regarding the presence of CSF leakage, the OR was 2.01 (95% CI 0.91 to 4.44).</P>
<P>We found no statistically significant differences for all-cause mortality in the eight studies in which relevant data were available (<LINK REF="STD-Ash-1992" TYPE="STUDY">Ash 1992</LINK>; <LINK REF="STD-Einhorn-1978" TYPE="STUDY">Einhorn 1978</LINK>; <LINK REF="STD-Frazee-1988" TYPE="STUDY">Frazee 1988</LINK>; <LINK REF="STD-Friedman-2001" TYPE="STUDY">Friedman 2001</LINK>; <LINK REF="STD-Ignelzi-1975b" TYPE="STUDY">Ignelzi 1975b</LINK>; <LINK REF="STD-MacGee-1970" TYPE="STUDY">MacGee 1970</LINK>; <LINK REF="STD-McGuirt-1995" TYPE="STUDY">McGuirt 1995</LINK>; <LINK REF="STD-Zrebeet-1986" TYPE="STUDY">Zrebeet 1986</LINK>). These included 460 participants in the treatment group and 265 in the control group (random-effects model OR 0.78; 95% CI 0.26 to 2.28). We found no significant differences for meningitis-related mortality (random-effects model OR 0.43; 95% CI 0.08 to 2.29).</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2015-04-06 19:29:24 +1000" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]">
<P>Curiously, the frequency of meningitis in the <LINK REF="STD-Eftekhar-2004" TYPE="STUDY">Eftekhar 2004</LINK> trial was significantly higher than in the other trials. The diagnosis of meningitis was based on cerebrospinal fluid (CSF) analysis in participants with compatible clinical findings and was comparable with the other trials. However, <LINK REF="STD-Eftekhar-2004" TYPE="STUDY">Eftekhar 2004</LINK> included only the subset of patients with basilar skull fractures and pneumocephalus that is associated with a dural tear with an open communication with air in the paranasal sinuses, mastoid air cells or petrous temporal regions and the central nervous system (CNS). These participants with pneumocephalus might have had an additional risk factor for developing meningitis that may have been independent of CSF leakage. The same authors developed a trial with the intent to clarify this hypothesis but it was not completed and no data were available upon contacting the author (<LINK REF="REF-Eftekhar-2006" TYPE="REFERENCE">Eftekhar 2006</LINK>). Further investigations are necessary to clarify this issue.</P>
<P>Given the current data, it is not possible to recommend the use of prophylactic antibiotics in patients with basilar skull fractures. Our results did not show that the administration of antibiotics had an effect on the frequency of meningitis. No significant difference was found in the subgroup of participants with CSF leakage, although there was a tendency to favour the treatment group. Again, no significant difference was found for all-cause or meningitis-related mortality. Although no significant differences were found, the confidence interval (CI) for all outcomes was wide and we could not exclude the possibility that antibiotic prophylaxis is either better or worse than the control. This is partially explained by the relatively small number of participants enrolled and the small number of events recorded.</P>
<P>The global results of the analysis of data extracted from the excluded studies are in agreement with the randomised data. Subgroup analysis within the excluded trials suggests a benefit from antibiotic prophylaxis in patients with CSF leakage. However, treatment interventions caused significantly more meningitis in the subgroup of patients without specification regarding CSF leakage status. These analyses should be read with caution since they are based mostly on retrospective studies and the data are not randomised. Additionally, the types of participants, interventions, diagnoses and outcome measures were significantly different between these studies. This makes the data difficult to interpret. Nevertheless, we thought it would be interesting to compare data from randomised controlled trials (RCTs) with non-RCTs since non-randomised studies tend to overestimate treatment effect size, which may be the case here.</P>
<P>According to the frequency of events in the treatment and control groups, and the relative risk for meningitis in the subgroup of patients with CSF leakage (0.64), a sample size of 798 participants was needed in order to show a statistically significant result between the two interventions, with a power of 90% and the probability of a type I error of 5%. This figure is similar when considering the data from the non-randomised case-controlled studies for the subgroup of patients with CSF leakage, for which the sample size necessary to show a significant result was 737 patients.</P>
<P>This is the first systematic review to study the effect of prophylactic antibiotics in basilar skull fractures. Based on the analysis of five RCTs, there is insufficient evidence to support or refute the use of antibiotics to prevent meningitis in patients with basilar skull fractures.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2015-02-26 20:09:22 +1000" MODIFIED_BY="[Empty name]">
<P>There is no support for routine prophylactic antibiotics in all patients with a basilar skull fracture. Further RCTs are needed to assess the benefits and risks clearly.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2015-04-06 19:29:24 +1000" MODIFIED_BY="[Empty name]">
<P>The quality of the evidence available to evaluate the use of prophylactic antibiotics in basilar skull fractures was indicated by the identification of only five RCTs that we considered suitable for this review. Even these had important methodological shortcomings. In general, the quality of the included trials was poor, as assessed by the 'Risk of bias' tool (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). All trials used a per-protocol based analysis. For the <LINK REF="STD-Eftekhar-2004" TYPE="STUDY">Eftekhar 2004</LINK> trial we had access to unpublished data that allowed us to perform some comparisons. We were able to study a total of 208 participants.</P>
<P>We assessed the quality of evidence using the GRADE method (<LINK REF="REF-GRADEpro-2014" TYPE="REFERENCE">GRADEpro 2014</LINK>). We judged the quality of evidence for the effect on frequency of meningitis, all-cause mortality and meningitis-related mortality as being of moderate quality due to potential selection, detection and reporting bias in two of the four studies. We assessed the evidence for the effect on need for surgical correction for CSF leakage to be of low quality, since it was extracted from a single study with potential detection bias. We judged the evidence on the effect of antibiotic prophylaxis on the frequency of non-CNS infections as high quality, as there were few concerns regarding inconsistency, indirectness or imprecision, with low risk of bias of the RCT (See <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2015-04-06 18:50:06 +1000" MODIFIED_BY="[Empty name]">
<P>We attempted to minimise publication bias by checking the reference lists of all related studies for further references and searching multiple databases with a comprehensive search strategy without any language restrictions; we did not identify any ongoing trials in three clinical trial registries. We believe we reduced other sources of bias by having three authors independently conducting the study selection, quality assessment and data extraction.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2015-03-01 18:24:21 +1000" MODIFIED_BY="[Empty name]">
<P>Despite the commonality of antibiotic prophylaxis in the treatment of basilar skull fractures, surprisingly no systematic review had previously specifically evaluated the efficacy of this treatment. We found two meta-analyses with conflicting conclusions: Brodie concluded there is a benefit of antibiotic prophylaxis (reducing the incidence of meningitis in patients with post-traumatic cerebrospinal fluid (CSF) leakage), whilst Villalobos found no decrease in meningitis in patients with basilar skull fractures (with or without CSF leakage) afforded antibiotic prophylaxis (<LINK REF="REF-Brodie-1997" TYPE="REFERENCE">Brodie 1997</LINK>; <LINK REF="REF-Villalobos-1998" TYPE="REFERENCE">Villalobos 1998</LINK>). The findings of our systematic review are similar to those in the Villalobos meta-analysis.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]">
<P>This systematic review did not show that prophylactic antibiotics had an effect on the prevention of meningitis in patients with basilar skull fractures, regardless of cerebrospinal fluid (CSF) leakage. Currently available evidence from RCTs does not support the use of prophylactic antibiotics in patients with basilar skull fractures. The risk of adverse reactions and financial costs are factors that should be taken into account when deciding if antibiotic therapy is appropriate.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]">
<P>More appropriately designed RCTs to test the effectiveness of prophylactic antibiotic use following the diagnosis of basilar skull fracture are needed in order to establish whether or not there is a net benefit from this intervention. Until more research results are available, firm conclusions regarding the efficacy of this treatment cannot be provided. Future trials should evaluate all clinically relevant outcomes (all-cause mortality, need for surgical correction in patients with CSF leakage, disability), not only central nervous system infection endpoints, and should pay attention to subgroups of patients, such as those with CSF leakage or pneumocephalus (or both).</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]">
<P>We are grateful to all members of the Cochrane Acute Respiratory Infections Group, namely Elizabeth Dooley, Sarah Thorning and Professor Chris Del Mar, for their continual assistance and to Marta Roque and Josep Garcia for conducting some of the electronic searches. We also wish to thank Stephanie Kondos, Jonathan Wasserberg, José Luis Ferrero Albert, Nelcy Rodriguez and Kameshwar Prasad for commenting on the draft review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2015-01-06 11:23:18 +1000" MODIFIED_BY="Liz  Dooley">
<P>Bernardo O Ratilal: none known.<BR/>João Costa: none known.<BR/>Cristina Sampaio: none known.<BR/>Lia Pappamikail: none known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2015-02-26 20:18:46 +1000" MODIFIED_BY="[Empty name]">
<P>2014 updated review: Bernardo O Ratilal (BR), João Costa (JC), Cristina Sampaio (CS), Lia Pappamikail (LP).</P>
<P>All correspondence: BR, LP.<BR/>Drafting of review versions: BR, JC, LP.<BR/>Searching for trials: BR, JC, LP.<BR/>Obtaining copies of trial reports: BR, LP.<BR/>Selection of trials for inclusion and exclusion: BR, JC, LP.<BR/>Extraction of data: BR, JC, LP.<BR/>Entry of data (into <LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>): BR, LP.<BR/>Interpretation of data analyses: BR, JC, LP, CS.<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2014-11-27 11:15:11 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Searching other sources</B>
</P>
<P>We were unable to handsearch the abstracts from the meeting proceedings of the European Association of Neurosurgical Societies (EANS) in this updated review as we do not have access to these sources.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2014-11-27 19:39:08 +1000" MODIFIED_BY="[Empty name]"/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2015-04-06 19:39:46 +1000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2015-02-26 03:29:54 +1000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2011-05-19 21:27:04 +1000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Demetriades-1992" MODIFIED="2011-05-19 21:26:51 +1000" MODIFIED_BY="[Empty name]" NAME="Demetriades 1992" YEAR="1992">
<REFERENCE MODIFIED="2011-05-19 21:26:51 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Demetriades D, Charalambides D, Lakhoo M, Pantanowitz D</AU>
<TI>Role of prophylactic antibiotics in open and basilar fractures of the skull: a randomized study</TI>
<SO>Injury</SO>
<YR>1992</YR>
<VL>23</VL>
<NO>6</NO>
<PG>377-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eftekhar-2004" MODIFIED="2011-05-19 21:26:54 +1000" MODIFIED_BY="[Empty name]" NAME="Eftekhar 2004" YEAR="2004">
<REFERENCE MODIFIED="2011-05-19 21:26:54 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eftekhar B, Ghodsi M, Nejat F, Ketabchi E, Esmaeeli B</AU>
<TI>Prophylactic administration of ceftriaxone for the prevention of meningitis after traumatic pneumocephalus: results of a clinical trial</TI>
<SO>Journal of Neurosurgery</SO>
<YR>2004</YR>
<VL>101</VL>
<NO>5</NO>
<PG>757-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hoff-1976" MODIFIED="2011-05-19 21:26:57 +1000" MODIFIED_BY="[Empty name]" NAME="Hoff 1976" YEAR="1976">
<REFERENCE MODIFIED="2011-05-19 21:26:57 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Hoff JT, Brewin A, U Hoi Sang . Letter: Antibiotics for basilar skull fracture. J Neurosurg 1976M;44:649.&lt;br&gt;Hoi Sang U&lt;/p&gt;" NOTES_MODIFIED="2011-05-19 21:26:57 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hoff JT, Brewin A, Hoi Sang U</AU>
<TI>Antibiotics for basilar skull fracture [letter]</TI>
<SO>Journal of Neurosurgery</SO>
<YR>1976</YR>
<VL>44</VL>
<NO>5</NO>
<PG>649</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ignelzi-1975a" MODIFIED="2011-05-19 21:27:00 +1000" MODIFIED_BY="[Empty name]" NAME="Ignelzi 1975a" YEAR="1975">
<REFERENCE MODIFIED="2011-05-19 21:27:00 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ignelzi R, VanderArk G</AU>
<TI>Analysis of the treatment of basilar skull fractures with and without antibiotics</TI>
<SO>Journal of Neurosurgery</SO>
<YR>1975</YR>
<VL>43</VL>
<NO>6</NO>
<PG>721-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Klastersky-1976" MODIFIED="2011-05-19 21:27:04 +1000" MODIFIED_BY="[Empty name]" NAME="Klastersky 1976" YEAR="1976">
<REFERENCE MODIFIED="2011-05-19 21:27:04 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klastersky J, Sadeghi M, Brihaye J</AU>
<TI>Antimicrobial prophylaxis in patients with rhinorrhea or otorrhea: a double blind study</TI>
<SO>Surgical Neurology</SO>
<YR>1976</YR>
<VL>6</VL>
<NO>2</NO>
<PG>111-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2015-02-26 03:29:54 +1000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Ash-1992" MODIFIED="2011-05-19 21:27:08 +1000" MODIFIED_BY="[Empty name]" NAME="Ash 1992" YEAR="1992">
<REFERENCE MODIFIED="2011-05-19 21:27:08 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ash GJ, Peter J, Bass DH</AU>
<TI>Antimicrobial prophylaxis for fractured base of skull in children</TI>
<SO>Brain Injury</SO>
<YR>1992</YR>
<VL>6</VL>
<NO>6</NO>
<PG>521-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bellamy-2013" MODIFIED="2014-12-19 14:17:15 +1000" MODIFIED_BY="Liz  Dooley" NAME="Bellamy 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-12-19 14:17:15 +1000" MODIFIED_BY="Liz  Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bellamy JL, Molendijk J, Reddy SK, Flores JM, Mundinger GS, Manson PN, et al</AU>
<TI>Severe infectious complications following frontal sinus fracture: the impact of operative delay and perioperative antibiotic use</TI>
<SO>Plastic Reconstructive Surgery</SO>
<YR>2013</YR>
<VL>132</VL>
<NO>1</NO>
<PG>154-62</PG>
<IDENTIFIERS MODIFIED="2014-10-23 03:44:22 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-10-23 03:44:22 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1097/PRS.0b013e3182910b9"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Choi-1996" MODIFIED="2011-05-19 21:27:13 +1000" MODIFIED_BY="[Empty name]" NAME="Choi 1996" YEAR="1996">
<REFERENCE MODIFIED="2011-05-19 21:27:13 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Choi D, Spann R</AU>
<TI>Traumatic cerebrospinal fluid leakage: risk factors and the use of prophylactic antibiotics</TI>
<SO>British Journal of Neurosurgery</SO>
<YR>1996</YR>
<VL>10</VL>
<NO>6</NO>
<PG>571-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Clemenza-1995" MODIFIED="2011-05-19 21:27:16 +1000" MODIFIED_BY="[Empty name]" NAME="Clemenza 1995" YEAR="1995">
<REFERENCE MODIFIED="2011-05-19 21:27:16 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clemenza JW, Kaltman SI, Diamond DL</AU>
<TI>Craniofacial trauma and cerebrospinal fluid leakage: a retrospective clinical study</TI>
<SO>Journal of Oral and Maxillofacial Surgery</SO>
<YR>1995</YR>
<VL>53</VL>
<NO>9</NO>
<PG>1004-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dagi-1983" MODIFIED="2011-05-19 21:27:21 +1000" MODIFIED_BY="[Empty name]" NAME="Dagi 1983" YEAR="1983">
<REFERENCE MODIFIED="2011-05-19 21:27:21 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dagi TF, Meyer FB, Poletti CA</AU>
<TI>The incidence and prevention of meningitis after basilar skull fracture</TI>
<SO>American Journal of Emergency Medicine</SO>
<YR>1983</YR>
<VL>1</VL>
<NO>3</NO>
<PG>295-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Einhorn-1978" MODIFIED="2011-05-19 21:27:26 +1000" MODIFIED_BY="[Empty name]" NAME="Einhorn 1978" YEAR="1978">
<REFERENCE MODIFIED="2011-05-19 21:27:26 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Einhorn A, Mizrahi EM</AU>
<TI>Basilar skull fractures in children. The incidence of CNS infection and the use of antibiotics</TI>
<SO>American Journal of Diseases of Children</SO>
<YR>1978</YR>
<VL>132</VL>
<NO>11</NO>
<PG>1121-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eljamel-1993" MODIFIED="2011-05-19 21:27:29 +1000" MODIFIED_BY="[Empty name]" NAME="Eljamel 1993" YEAR="1993">
<REFERENCE MODIFIED="2011-05-19 21:27:29 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eljamel MS</AU>
<TI>Antibiotic prophylaxis in unrepaired CSF fistulae</TI>
<SO>British Journal of Neurosurgery</SO>
<YR>1993</YR>
<VL>7</VL>
<NO>5</NO>
<PG>501-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Frazee-1988" MODIFIED="2011-05-19 21:27:33 +1000" MODIFIED_BY="[Empty name]" NAME="Frazee 1988" YEAR="1988">
<REFERENCE MODIFIED="2011-05-19 21:27:33 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Frazee RC, Mucha P Jr, Farnell MB, Ebersold MJ</AU>
<TI>Meningitis after basilar skull fracture. Does antibiotic prophylaxis help?</TI>
<SO>Postgraduate Medicine</SO>
<YR>1988</YR>
<VL>83</VL>
<NO>5</NO>
<PG>267-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Friedman-2001" MODIFIED="2011-05-19 21:27:36 +1000" MODIFIED_BY="[Empty name]" NAME="Friedman 2001" YEAR="2001">
<REFERENCE MODIFIED="2011-05-19 21:27:36 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Friedman JA, Ebersold MJ, Quast LM</AU>
<TI>Post-traumatic cerebrospinal fluid leakage</TI>
<SO>World Journal of Surgery</SO>
<YR>2001</YR>
<VL>25</VL>
<NO>8</NO>
<PG>1062-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gonzalez-1998" MODIFIED="2011-05-19 21:27:40 +1000" MODIFIED_BY="[Empty name]" NAME="Gonzalez 1998" YEAR="1988">
<REFERENCE MODIFIED="2011-05-19 21:27:40 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Full journal title - Revista Cubana de Cirug&amp;#237;a&lt;br&gt;The title was not given in english but it means something like 'antibiotic prophylaxis in basilar skull fractures. Does it worth it?'&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2011-05-19 21:27:40 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gonzalez JL</AU>
<TI>Antibiotic prophylaxis in basilar skull fractures. Is it worth it?</TI>
<TO>Profilaxis con antibioticos en fracturas de base de craneo. Tiene justification esa conducta?</TO>
<SO>Revista Cubana de Cirugía</SO>
<YR>1998</YR>
<VL>37</VL>
<NO>2</NO>
<PG>5-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Helling-1988" MODIFIED="2011-05-19 21:27:44 +1000" MODIFIED_BY="[Empty name]" NAME="Helling 1988" YEAR="1988">
<REFERENCE MODIFIED="2011-05-19 21:27:44 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Helling TS, Evans LL, Fowler DL, Hays LV, Kennedy FR</AU>
<TI>Infectious complications in patients with severe head injury</TI>
<SO>Journal of Trauma</SO>
<YR>1988</YR>
<VL>28</VL>
<NO>11</NO>
<PG>1575-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ibrahim-2012" MODIFIED="2014-12-02 10:36:58 +1000" MODIFIED_BY="Liz  Dooley" NAME="Ibrahim 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-12-02 10:36:58 +1000" MODIFIED_BY="Liz  Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ibrahim AA, Magdy EA, Eid M</AU>
<TI>Endoscopic endonasal multilayer repair of traumatic ethmoidal roof cerebrospinal roof rhinorrhea in children</TI>
<SO>International Journal of Pediatric Otorhinolaryngology</SO>
<YR>2012</YR>
<VL>76</VL>
<PG>523-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ignelzi-1975b" MODIFIED="2011-05-19 21:27:50 +1000" MODIFIED_BY="[Empty name]" NAME="Ignelzi 1975b" YEAR="1975">
<REFERENCE MODIFIED="2011-05-19 21:27:50 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ignelzi R, VanderArk G</AU>
<TI>Analysis of the treatment of basilar skull fractures with and without antibiotics</TI>
<SO>Journal of Neurosurgery</SO>
<YR>1975</YR>
<VL>43</VL>
<NO>6</NO>
<PG>721-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lauder-2009" MODIFIED="2014-12-02 10:38:04 +1000" MODIFIED_BY="Liz  Dooley" NAME="Lauder 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-12-02 10:38:04 +1000" MODIFIED_BY="Liz  Dooley" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Lauder A, Devaiah BA, Devaiah A</AU>
<TI>Antibiotic prophylaxis in the surgical management of facial trauma</TI>
<SO>Boston Medical Center &amp; Boston University School of Medicine</SO>
<YR>2009</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-MacGee-1970" MODIFIED="2011-05-19 21:27:47 +1000" MODIFIED_BY="[Empty name]" NAME="MacGee 1970" YEAR="1970">
<REFERENCE MODIFIED="2011-05-19 21:27:47 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>MacGee EE, Cauthen JC, Brackett CE</AU>
<TI>Meningitis following acute traumatic cerebrospinal fluid fistula</TI>
<SO>Journal of Neurosurgery</SO>
<YR>1970</YR>
<VL>33</VL>
<NO>3</NO>
<PG>312-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McGuirt-1995" MODIFIED="2011-05-19 21:27:53 +1000" MODIFIED_BY="[Empty name]" NAME="McGuirt 1995" YEAR="1995">
<REFERENCE MODIFIED="2011-05-19 21:27:53 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McGuirt WF Jr, Stool SE</AU>
<TI>Cerebrospinal fluid fistula: the identification and management in pediatric temporal bone fractures</TI>
<SO>Laryngoscope</SO>
<YR>1995</YR>
<VL>105</VL>
<NO>4 Pt 1</NO>
<PG>359-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prosser-2011" MODIFIED="2014-12-15 09:56:53 +1000" MODIFIED_BY="[Empty name]" NAME="Prosser 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-12-15 09:56:53 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prosser JD, Vender JR, Solares CA</AU>
<TI>Traumatic cerebrospinal fluid leaks</TI>
<SO>Otolaryngology Clinics North America</SO>
<YR>2011</YR>
<VL>44</VL>
<PG>857-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Raskind-1965" MODIFIED="2011-05-19 21:27:57 +1000" MODIFIED_BY="[Empty name]" NAME="Raskind 1965" YEAR="1965">
<REFERENCE MODIFIED="2011-05-19 21:27:57 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Raskind R</AU>
<TI>Cerebrospinal fluid rhinorrhea and otorrhea. Diagnosis and treatment in 35 cases</TI>
<SO>Journal of the International College of Surgeons</SO>
<YR>1965</YR>
<VL>43</VL>
<PG>141-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sherif-2012" MODIFIED="2014-12-19 14:17:37 +1000" MODIFIED_BY="Liz  Dooley" NAME="Sherif 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-12-19 14:17:37 +1000" MODIFIED_BY="Liz  Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sherif C, Di Ieva A, Gibson D, Pakrah-Bodingbauer B, Widhalm G, Krusche-Mandl I, et al</AU>
<TI>A management algorithm for cerebrospinal fluid leak associated with anterior skull base fractures: detailed clinical and radiological follow-up</TI>
<SO>Neurosurgical Review</SO>
<YR>2012</YR>
<VL>35</VL>
<PG>227-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Steidtmann-1997" MODIFIED="2011-05-19 21:28:00 +1000" MODIFIED_BY="[Empty name]" NAME="Steidtmann 1997" YEAR="1997">
<REFERENCE MODIFIED="2011-05-19 21:28:00 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Steidtmann K, Welge-Lussen A, Probst R</AU>
<TI>Antibiotic prophylaxis in laterobasal fractures</TI>
<TO>Antibiotikaprophylaxe bei laterobasalen frakturen</TO>
<SO>HNO</SO>
<YR>1997</YR>
<VL>45</VL>
<NO>6</NO>
<PG>448-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tos-1973" MODIFIED="2011-05-19 21:28:04 +1000" MODIFIED_BY="[Empty name]" NAME="Tos 1973" YEAR="1973">
<REFERENCE MODIFIED="2011-05-19 21:28:04 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tos M</AU>
<TI>Course of and sequelae to 248 petrosal fractures</TI>
<SO>Acta Otolaryngologica (Stockholm)</SO>
<YR>1973</YR>
<VL>75</VL>
<NO>4</NO>
<PG>353-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zix-2013" MODIFIED="2014-12-18 10:39:58 +1000" MODIFIED_BY="[Empty name]" NAME="Zix 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-12-18 10:39:58 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Zix J, Schaller B, Iizuka T, Lieger O</AU>
<TI>The role of postoperative prophylactic antibiotics in the treatment of facial fractures: a randomised, double-blind, placebo-controlled pilot clinical study. Part 1: orbital fractures in 62 patients</TI>
<SO>British Journal of Oral and Maxillofacial Surgery</SO>
<YR>2013</YR>
<VL>51</VL>
<PG>332-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zrebeet-1986" MODIFIED="2015-02-26 03:29:54 +1000" MODIFIED_BY="[Empty name]" NAME="Zrebeet 1986" YEAR="1986">
<REFERENCE MODIFIED="2011-05-19 21:28:08 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zrebeet HA, Huang PS</AU>
<TI>Prophylactic antibiotics in the treatment of fractures at the base of the skull</TI>
<SO>Delaware Medical Journal</SO>
<YR>1986</YR>
<VL>58</VL>
<NO>11</NO>
<PG>741-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2014-12-18 10:17:16 +1000" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2015-04-06 19:39:46 +1000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2015-04-06 19:39:46 +1000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Balshem-2011" MODIFIED="2015-04-06 19:28:40 +1000" MODIFIED_BY="[Empty name]" NAME="Balshem 2011" TYPE="JOURNAL_ARTICLE">
<AU>Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et al</AU>
<TI>GRADE guidelines: 3. Rating the quality of evidence</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>4</NO>
<PG>401-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brodie-1997" NAME="Brodie 1997" TYPE="JOURNAL_ARTICLE">
<AU>Brodie HA</AU>
<TI>Prophylactic antibiotics for posttraumatic cerebrospinal fluid fistulae. A meta-analysis</TI>
<SO>Archives of Otolaryngology - Head and Neck Surgery</SO>
<YR>1997</YR>
<VL>123</VL>
<NO>7</NO>
<PG>749-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Buchanan-2004" NAME="Buchanan 2004" TYPE="BOOK_SECTION">
<AU>Buchanan RJ, Brant A, Marshall LR</AU>
<TI>Traumatic cerebrospinal fluid fistulas</TI>
<SO>Youmans Neurological Surgery</SO>
<YR>2004</YR>
<PG>5265-72</PG>
<EN>5th</EN>
<ED>Winn H</ED>
<PB>Saunders</PB>
<CY>Philadelphia</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dickersin-1994" NAME="Dickersin 1994" NOTES="&lt;p&gt;Dickersin 1994. Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ 1994; 309:1286-91.&lt;br&gt;&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Dickersin K, Scherer R, Lefebvre C</AU>
<TI>Identifying relevant studies for systematic reviews</TI>
<SO>BMJ</SO>
<YR>1994</YR>
<VL>309</VL>
<PG>1286-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Eftekhar-2006" MODIFIED="2014-12-18 10:16:52 +1000" MODIFIED_BY="[Empty name]" NAME="Eftekhar 2006" TYPE="JOURNAL_ARTICLE">
<AU>Eftekhar B, Ghodsi M, Hadadi A, Taghipoor M, Sigarchi SZ, Rahimi-Movaghar V, et al</AU>
<TI>Prophylactic antibiotic for prevention of posttraumatic meningitis after traumatic pneumocephalus: design and rationale of a placebo-controlled randomized multicenter trial</TI>
<SO>Trials</SO>
<YR>2006</YR>
<VL>18</VL>
<NO>7</NO>
<PG>2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-2001" MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]" NAME="Egger 2001" TYPE="BOOK">
<AU>Egger M, Smith GD, Altman DG</AU>
<SO>Systematic Reviews in Health Care. Meta-analysis in Context</SO>
<YR>2001</YR>
<EN>2nd</EN>
<PB>BMJ Books</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-GRADEpro-2014" MODIFIED="2015-04-06 19:29:34 +1000" MODIFIED_BY="[Empty name]" NAME="GRADEpro 2014" TYPE="COMPUTER_PROGRAM">
<TI>GRADEpro [Computer program on www.gradepro.org] [Computer program]. Version 3.6</TI>
<YR>2014</YR>
<PB>McMaster University</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2002" MODIFIED="2015-04-06 19:32:32 +1000" MODIFIED_BY="[Empty name]" NAME="Higgins 2002" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG</AU>
<TI>Quantifying heterogeneity in a meta-analysis</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<NO>11</NO>
<PG>1539-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leech-1973" NAME="Leech 1973" TYPE="JOURNAL_ARTICLE">
<AU>Leech PJ, Paterson A</AU>
<TI>Conservative and operative management of cerebrospinal fluid leakage after closed head injury</TI>
<SO>Lancet</SO>
<YR>1973</YR>
<VL>1</VL>
<PG>1013-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2014" MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]" NAME="RevMan 2014" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2014</YR>
<EN>5.3</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sch_x00fc_nemann-2011" MODIFIED="2015-04-06 19:39:46 +1000" MODIFIED_BY="[Empty name]" NAME="Schünemann 2011" TYPE="OTHER">
<AU>Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al</AU>
<TI>Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sterne-2011" MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]" NAME="Sterne 2011" TYPE="OTHER">
<AU>Sterne JAC, Egger M, Moher D (editors)</AU>
<TI>Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Villalobos-1998" NAME="Villalobos 1998" TYPE="JOURNAL_ARTICLE">
<AU>Villalobos T, Arango C, Kubilis P, Rathore M</AU>
<TI>Antibiotic prophylaxis after basilar skull fractures: a meta-analysis</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>1998</YR>
<VL>27</VL>
<PG>364-9</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2014-12-19 14:19:33 +1000" MODIFIED_BY="Liz  Dooley">
<REFERENCE ID="REF-Ratilal-2004" MODIFIED="2014-12-19 14:19:33 +1000" MODIFIED_BY="Liz  Dooley" NAME="Ratilal 2004" TYPE="COCHRANE_PROTOCOL">
<AU>Ratilal B, Costa J, Sampaio C</AU>
<TI>Antibiotic prophylaxis for preventing meningitis in patients with basilar skull fractures</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2014-12-19 14:19:23 +1000" MODIFIED_BY="Liz  Dooley">
<IDENTIFIER MODIFIED="2014-12-19 14:19:23 +1000" MODIFIED_BY="Liz  Dooley" TYPE="DOI" VALUE="10.1002/14651858.CD004884"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ratilal-2006" MODIFIED="2014-12-02 11:03:06 +1000" MODIFIED_BY="Liz  Dooley" NAME="Ratilal 2006" TYPE="COCHRANE_REVIEW">
<AU>Ratilal B, Costa J, Sampaio C</AU>
<TI>Antibiotic prophylaxis for preventing meningitis in patients with basilar skull fractures</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2014-12-02 11:03:06 +1000" MODIFIED_BY="Liz  Dooley">
<IDENTIFIER MODIFIED="2014-12-02 11:03:06 +1000" MODIFIED_BY="Liz  Dooley" TYPE="DOI" VALUE="10.1002/14651858.CD004884.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ratilal-2011" MODIFIED="2014-12-02 11:04:59 +1000" MODIFIED_BY="Liz  Dooley" NAME="Ratilal 2011" TYPE="COCHRANE_REVIEW">
<AU>Ratilal B, Costa J, Sampaio C, Pappamikail L</AU>
<TI>Antibiotic prophylaxis for preventing meningitis in patients with basilar skull fractures</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>8</NO>
<IDENTIFIERS MODIFIED="2014-12-02 11:04:03 +1000" MODIFIED_BY="Liz  Dooley">
<IDENTIFIER MODIFIED="2014-12-02 11:04:03 +1000" MODIFIED_BY="Liz  Dooley" TYPE="DOI" VALUE="10.1002/14651858.CD004884.pub3"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Demetriades-1992">
<CHAR_METHODS>
<P>Randomised, controlled, 3 arms<BR/>Method of randomisation: not specified<BR/>Location: 1 centre in South Africa<BR/>Duration: 1 year</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: patients with an open skull fracture or a BSF (diagnosed radiologically or clinically)<BR/>Exclusion criteria: GCS &lt; 6 or requiring neurosurgical intervention, or with major extracranial injuries<BR/>196 patients enrolled<BR/>There were 39 withdrawals: 5 because of violation of the protocol, 3 due to death within 5 days and 31 lost to follow-up<BR/>The 2 major groups (antibiotic (AB) or no AB) were statistically similar with regard to age, sex, cause of injury, type of fracture, GCS, bladder catheterisation, endotracheal intubation<BR/>37 patients with BSF were considered for the review:<BR/>N = 12 group A<BR/>N = 14 group B<BR/>N = 11 group C<BR/>CSF leakage:<BR/>N = 9 group A<BR/>N = 14 group B<BR/>N = 5 group C</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-05-19 21:23:39 +1000" MODIFIED_BY="[Empty name]">
<P>Patients were randomised to one of 3 groups: no antibiotics (group A), 1 g ceftriaxone IV daily for 3 days (group B) combined ampicillin (1 g IV 6-hourly)/sulphadiazine (0.5 g IV 6-hourly) (group C)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-05-19 21:23:50 +1000" MODIFIED_BY="[Empty name]">
<P>Primary outcome event was evidence of intracranial or extracranial infection (meningitis - suspected clinically and confirmed by lumbar puncture, brain abscess, wound sepsis, pneumonia, urinary tract infection)<BR/>Patients were followed for a minimal period of 10 days<BR/>Meningitis in patients with BSF:<BR/>Group A 1/12<BR/>Group B 0/14<BR/>Group C 0/11<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Eftekhar-2004">
<CHAR_METHODS>
<P>Randomised, controlled, not blinded, 2 arms<BR/>Method of randomisation: patients assigned according to a list of on-call physicians<BR/>Location: 1 centre in Iran<BR/>Duration: 27 months<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: acute traumatic pneumocephalus verified by CT scan<BR/>Exclusion criteria: AB therapy for other reasons; penetrating traumatic brain injury or open skull fracture; surgery for any reason; discharge from hospital without doctor's approval; life-threatening lesions including severe brain, abdominal or vascular injuries; death from other causes<BR/>109 patients enrolled:<BR/>PAT+ group N = 53<BR/>PAT- group N = 56<BR/>Both groups were well balanced with respect to their characteristics</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Patients were divided into 2 groups: PAT+ group in which prophylactic AB therapy was given (ceftriaxone, 1 g twice a day, continued for 5 days) and PAT- group in which no prophylactic AB therapy was given</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]">
<P>Primary outcome event was occurrence of meningitis (based on clinical and CSF findings)<BR/>Follow-up 1 month post-trauma<BR/>PAT+ group 10/53<BR/>PAT- group 12/56</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Author was contacted and kindly provided additional information</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hoff-1976">
<CHAR_METHODS>
<P>Randomised, controlled, blinded, 3 arms<BR/>Method of randomisation: not specified<BR/>Location: 1 centre in USA<BR/>Duration: not specified</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Inclusion criteria: diagnosis of BSF based on clinical or radiographic evidence<BR/>Exclusion criteria: previous allergy to penicillin; CSF leakage immediately after injury<BR/>160 patients enrolled<BR/>Numbers in each group not specified</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Patients were assigned randomly and blindly to one of 3 groups: <BR/>No AB given (group 1) <BR/>1.2 million units of penicillin given IV daily for 3 days (group 2) <BR/>20 million units of penicillin given IV daily for 3 days (group 3)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcome event was development of CNS infection<BR/>None of the patients enrolled developed signs or symptoms of CNS infection</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]">
<P>We contacted the author but further information was no longer available</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-05-19 21:24:58 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ignelzi-1975a">
<CHAR_METHODS>
<P>Randomised, controlled, 2 arms<BR/>Method of randomisation: not specified<BR/>Location: 1 centre in USA<BR/>Duration: not specified</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Inclusion criteria: diagnosis of BSF<BR/>Exclusion criteria: not specified</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-05-19 21:24:58 +1000" MODIFIED_BY="[Empty name]">
<P>Patients were randomised into 2 groups: one group received prophylactic ampicillin or cephalothin 1 g 6-hourly for 10 days and the other did not receive AB</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcome events were the development of CNS infection and change in the posterior nasopharyngeal flora<BR/>None of the patients developed meningitis</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>This article included both a RCT of 10 patients and a retrospective study of 129 patients<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Klastersky-1976">
<CHAR_METHODS>
<P>Randomised, placebo-controlled, double-blind, 2 arms<BR/>Method of randomisation: vials containing AB or placebo were distributed in boxes designated by code numbers only <BR/>Location: 1 centre in Belgium<BR/>Duration: not specified<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: recent cranial trauma and rhinorrhoea or otorrhoea<BR/>No clear exclusion criteria defined<BR/>AB group N = 26<BR/>Placebo group N = 26<BR/>Age, sex, presence of diseases other than the cranial trauma and prognosis at the time of admission had similar frequency in both groups</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-05-19 21:25:25 +1000" MODIFIED_BY="[Empty name]">
<P>Patients were randomised into 2 groups: one group received prophylactic 5 mega units of penicillin G IV 6-hourly with a mean duration of 7.7 days (range 4 to 13 days) and the other group received placebo under identical conditions</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Outcome events were: <BR/>Development of meningitis (positive CSF culture: AB group 0/26, placebo group 1/26) <BR/>Possible CNS infection, other serious infection (pulmonary, urinary tract) <BR/>Death from brain damage (AB group 4/26, placebo group 3/26) <BR/>Bacterial colonisations of bronchial secretions or urine</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>AB: antibiotic<BR/>BSF: basilar skull fracture<BR/>CNS: central nervous system<BR/>CSF: cerebrospinal fluid<BR/>CT: computed tomography<BR/>GCS: Glasgow Coma Scale<BR/>IV: intravenous<BR/>N: number<BR/>PAT+: prophylactic antibiotic treatment given<BR/>PAT-: prophylactic antibiotic treatment not given<BR/>RCT: randomised controlled trial<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ash-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]">
<P>Retrospective controlled study that reviewed 48 children with BSF, comparing empirical choice of AB prophylaxis (penicillin and chloramphenicol or co-trimoxazole alone, N = 23) with no prophylaxis (N = 25)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-18 10:37:24 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bellamy-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-18 10:37:24 +1000" MODIFIED_BY="[Empty name]">
<P>Retrospective chart review of all admitted patients with frontal sinus fracture (with or without skull base involvement), all receiving antibiotic treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Choi-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]">
<P>Retrospective controlled study that reviewed 270 patients with evidence of CSF leakage or BSF and compared the incidence of meningitis in those who received AB prophylaxis (type and duration depending on consultant preference, N = 197) versus those who did not (N = 73)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Clemenza-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]">
<P>Retrospective controlled study that reviewed 88 patients with traumatic CSF leakage and the use of prophylactic AB to prevent meningitis (any or combination of penicillin, chloramphenicol, ampicillin, nafcillin or claforan, observational N = 48) compared with no AB (N = 40)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dagi-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]">
<P>Retrospective controlled study that evaluated 163 patients with BSF, either with or without CSF leak, and compared the incidence of meningitis in the group that had received prophylactic AB (N = 91) with the group that did not (N = 72)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Einhorn-1978">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]">
<P>Retrospective controlled study that reviewed 46 patients up to 15 years of age with BSF and the clinical course of those who were treated with antimicrobial prophylaxis or AB for other reasons (N = 14) compared to those who did not receive any AB (N = 32)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Eljamel-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]">
<P>Retrospective controlled study that evaluated the possible effects of prophylactic AB treatment in 215 patients with unrepaired traumatic CSF leak. AB prophylaxis (penicillin or sulfonamide) was considered to be adequate if started within 3 days of the onset of the CSF leak and continued for at least 1 week after the leakage stopped (either penicillin or sulphonamide, N = 106). The other group did not receive AB (N = 109). Diagnosis of meningitis was based on clinical signs and confirmation based on CSF chemistry if no growth isolation of a pathogen form</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Frazee-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]">
<P>Retrospective controlled study. 347 patients with BSF were divided into 2 groups reflecting the individual physician's preference: one group treated prophylactically with AB (penicillin or synthetic penicillin either alone or in combination with another AB, usually an aminoglycoside, N = 251) and a second group initially observed only (N = 96)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Friedman-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]">
<P>Retrospective controlled study that enrolled 43 patients with clinically evident traumatic CSF leak 24 hours or more after injury and evaluated the frequency of meningitis among those who had prophylactic AB (N = 29) compared with those who did not (N = 14)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gonzalez-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]">
<P>Prospective observational study with historical control group. 380 patients with a clinical diagnosis of BSF enrolled. The prospective group received no AB (N = 309) and were compared with an historical control group that had had prophylactic AB (penicillin either alone or in combination with chloramphenicol or streptomycin, N = 71)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Helling-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Retrospective controlled study that evaluated infectious complications in patients with severe head injury. Frequency of meningitis was compared among 23 patients with a diagnosis of BSF who were divided into 2 groups: prophylactic AB (N = 12) and no AB (N = 11)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ibrahim-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]">
<P>Retrospective chart review study; no reference to antibiotic treatment; surgical technique case report</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-05-19 21:26:27 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ignelzi-1975b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-05-19 21:26:27 +1000" MODIFIED_BY="[Empty name]">
<P>Prospective observational study with historical group (authors also report a smaller RCT (N = 10), which is one of the included studies (<LINK REF="STD-Ignelzi-1975a" TYPE="STUDY">Ignelzi 1975a</LINK>)). 50 patients diagnosed with BSF and not treated with AB were studied prospectively and compared regarding infectious complications with an historical group of 54 patients who had the same diagnosis but who received prophylactic AB (mainly ampicillin or cephalothin)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lauder-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]">
<P>Retrospective controlled study. 223 patients with traumatic facial injury undergoing surgical repair were enrolled into 4 groups to study the effect of prophylactic AB: A (pre- and perioperatively, N = 6), B (perioperatively, N = 43), C (peri- and postoperatively, N = 106), D (pre-, peri- and postoperatively, N = 68). Different antibiotics and delivery routes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-MacGee-1970">
<CHAR_REASON_FOR_EXCLUSION>
<P>Retrospective controlled study. 58 patients with acute traumatic CSF fistula were enrolled into 2 groups to study the effect of prophylactic AB: 1 group that received AB (penicillin, chloramphenicol or sulfadiazine, N = 41) was compared with another group that did not receive AB (N = 17)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McGuirt-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]">
<P>Retrospective controlled group that evaluated 37 children with temporal bone fracture and strong clinical evidence of CSF fistula persisting for more than 24 hours. The use of prophylactic AB was not recommended but some patients (N = 20) received some form of AB therapy because of a concurrent injury, during fever evaluation or during periods of lumbar drainage. The other patients (N = 17) did not receive any form of AB</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-02 11:07:23 +1000" MODIFIED_BY="Liz  Dooley" STUDY_ID="STD-Prosser-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-02 11:07:23 +1000" MODIFIED_BY="Liz  Dooley">
<P>Review of the published medical literature</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Raskind-1965">
<CHAR_REASON_FOR_EXCLUSION>
<P>Retrospective controlled study. 35 patients with CSF leak were enrolled, among whom 28 were traumatic and divided into groups that received prophylactic AB (N = 15) or not (N = 13)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sherif-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]">
<P>Retrospective study, with all patients receiving antibiotics</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Steidtmann-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Retrospective controlled study. 78 patients who had suffered lateral skull base fractures with or without CSF leak were enrolled and the risk of meningitis among those who were given prophylactic AB (N = 23) was compared with those who were not (N = 55)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tos-1973">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]">
<P>Retrospective controlled study that reviewed the incidence of meningitis in 198 patients with petrosal fractures in groups treated with AB (N = 118) and without AB (N = 80)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-02 11:07:03 +1000" MODIFIED_BY="Liz  Dooley" STUDY_ID="STD-Zix-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-02 11:07:03 +1000" MODIFIED_BY="Liz  Dooley">
<P>Randomised controlled trial with both groups receiving prophylactic AB for 5 days (N = 29) or 1 day plus 4 days placebo (N = 31), for orbital blow-out fractures</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zrebeet-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]">
<P>Retrospective controlled study. 42 patients with a diagnosis of BSF were reviewed to evaluate the incidence of meningitis with prophylactic AB (various AB, N = 28) and without (N = 14)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>AB: antibiotic<BR/>BSF: basilar skull fracture<BR/>CSF: cerebrospinal fluid<BR/>N: number<BR/>RCT: randomised controlled trial<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES>
<P>
<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Demetriades-1992">
<DESCRIPTION>
<P>"The patients were randomised to receive no antibiotics (group A) or antibiotics for 3 days"; no specification of method of randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-18 10:32:35 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Eftekhar-2004">
<DESCRIPTION>
<P>"The patients were divided into two groups (...) according to a list of on-call physicians. The list did not have any predictable sequence"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hoff-1976">
<DESCRIPTION>
<P>"160 patients (...) were assigned randomly and blindly to one of three treatment groups"; no reference to the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ignelzi-1975a">
<DESCRIPTION>
<P>10 patients randomised; method of randomisation not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-21 09:57:14 +1000" MODIFIED_BY="Liz Dooley" RESULT="YES" STUDY_ID="STD-Klastersky-1976">
<DESCRIPTION>
<P>Vials containing penicillin or placebo in boxes with code number, which was only unveiled after diagnosis of infection or colonisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2011-04-19 15:23:04 +1000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-19 15:23:04 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Demetriades-1992">
<DESCRIPTION>
<P>Method of concealment is not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-19 15:22:41 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Eftekhar-2004">
<DESCRIPTION>
<P>Method of concealment is not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-19 15:22:23 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hoff-1976">
<DESCRIPTION>
<P>Method of concealment is not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-19 15:22:07 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ignelzi-1975a">
<DESCRIPTION>
<P>Method of concealment is not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-19 15:21:47 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Klastersky-1976">
<DESCRIPTION>
<P>Code numbered vials of identical appearance</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2011-05-12 07:10:20 +1000" MODIFIED_BY="Liz Dooley" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Demetriades-1992">
<DESCRIPTION>
<P>No blinding of personnel, due to identifiable differences in treatment options: "no antibiotics (group A) (...) ceftriaxone intravenously 1 g daily (a total of 3 injections) [group B] (...) ampicillin intravenously 1 g 6-hourly (a total of 12 injections) [group C])"; however, we judge that the outcome and the outcome measurement are not likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Eftekhar-2004">
<DESCRIPTION>
<P>No blinding of personnel; however, we judge that the outcome and the outcome measurement are not likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hoff-1976">
<DESCRIPTION>
<P>"160 patients (...) were assigned randomly and blindly to one of three treatment groups". No blinding of personnel, due to identifiable differences in treatment options, but we judge that the outcome and the outcome measurement are not likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ignelzi-1975a">
<DESCRIPTION>
<P>No blinding of personnel, due to identifiable differences in treatment options, but we judge that the outcome and the outcome measurement are not likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-04-28 08:18:11 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Klastersky-1976">
<DESCRIPTION>
<P>Blinding of participants and all personnel ensured, and not possible that the blinding had been broken</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Demetriades-1992">
<DESCRIPTION>
<P>Only identifiable difference between groups concerns treatment options (no antibiotic versus 2 different antibiotic treatments for 3 days), and we judge that the outcome and outcome measurement are not likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Eftekhar-2004">
<DESCRIPTION>
<P>Outcome measure with insensitive instrument in a parcel of the results; "five diagnoses were based only on clinical findings. No antibiograms were obtained"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hoff-1976">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-02-26 19:46:30 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ignelzi-1975a">
<DESCRIPTION>
<P>Only identifiable difference between groups concerns treatment options (no antibiotic versus antibiotic treatment), and we judge that the outcome and outcome measurement are not likely to be influenced by lack of blinding. Outcome measured by clinical signs and confirmed by lumbar puncture and posterior naso-oropharynx swab</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-04-28 08:21:42 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Klastersky-1976">
<DESCRIPTION>
<P>Blinding of participants and all personnel ensured, and not possible that the blinding had been broken</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2011-05-19 21:24:09 +1000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-19 21:24:09 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Demetriades-1992">
<DESCRIPTION>
<P>"39 cases were excluded because of violation of protocol, death within 5 days or lost to follow-up. Analysis was restricted to the remaining 157 cases". No comment is made as to the proportion of missing outcomes compared with observed event</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-04-19 15:22:34 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Eftekhar-2004">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-04-19 15:22:20 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hoff-1976">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-04-19 15:22:05 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ignelzi-1975a">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-04-19 15:21:44 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Klastersky-1976">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2011-05-19 21:24:53 +1000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-19 21:24:19 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Demetriades-1992">
<DESCRIPTION>
<P>The study protocol is not available, making it impossible to assess whether the outcomes reported were all pre-specified or not</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-19 15:22:33 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Eftekhar-2004">
<DESCRIPTION>
<P>The study protocol is available and all of the study's pre-specified outcomes that are of interest in the review have been reported in the pre-specified way</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-19 21:24:53 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hoff-1976">
<DESCRIPTION>
<P>The study protocol is not available, making it impossible to assess whether the outcomes reported were all pre-specified or not</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-19 15:22:04 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ignelzi-1975a">
<DESCRIPTION>
<P>The study protocol is available and all of the study's pre-specified outcomes that are of interest in the review have been reported in the pre-specified way</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-19 15:21:42 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Klastersky-1976">
<DESCRIPTION>
<P>The study protocol is available and all of the study's pre-specified outcomes that are of interest in the review have been reported in the pre-specified way</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2011-04-28 07:58:18 +1000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-19 15:22:59 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Demetriades-1992">
<DESCRIPTION>
<P>No other identifiable sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-28 07:58:18 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Eftekhar-2004">
<DESCRIPTION>
<P>No other identifiable sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-19 15:22:18 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hoff-1976">
<DESCRIPTION>
<P>Insufficient information to assess whether an important risk of bias exists</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-19 15:22:02 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ignelzi-1975a">
<DESCRIPTION>
<P>No other identifiable sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-19 15:21:41 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Klastersky-1976">
<DESCRIPTION>
<P>No other identifiable sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2015-04-06 17:23:59 +1000" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2015-04-06 17:23:59 +1000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2014-11-27 08:27:34 +1000" MODIFIED_BY="[Empty name]">Summary of findings</TITLE>
<TABLE COLS="5" ROWS="10">
<TR>
<TD COLSPAN="5">
<P>
<B>Antibiotic prophylaxis compared with placebo for preventing meningitis in BSF</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="5">
<P>
<B>Patient or population: </B>patients with a recent BSF independent of the presence or severity of CSF leakage</P>
<P>
<B>Settings: </B>in-hospital care</P>
<P>
<B>Intervention: </B>antibiotic prophylaxis</P>
<P>
<B>Comparison: </B>placebo</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH VALIGN="TOP">
<P>No. of participants<BR/>(studies)</P>
</TH>
<TH VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Frequency of meningitis</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>OR 0.69 (0.29 to 1.61)</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>208 (4)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>moderate<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>All-cause mortality</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>OR 1.68 (0.41 to 6.95)</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>208 (4)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>moderate<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Meningitis-related mortality</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>OR 1.03 (0.14 to 7.40)</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>208 (4)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>moderate<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Need for surgical correction in patients with CSF leakage</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>109 (1)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>low<SUP>2</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Non-CNS infection</B>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>
<B>OR 0.61 (0.15 to 2.46)</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>52 (1)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>high</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="5">
<P>
<B>BSF</B>: basilar skull fracture; <B>CI:</B> confidence interval;<B> CNS:</B> central nervous system; <B>CSF:</B> cerebrospinal fluid; <B>OR:</B> odds ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="5">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Downgraded for limitations in study design as two of the four studies had unclear blinding of allocation and outcome assessment leading to possible selection and detection bias; also unclear risk of reporting bias in one study.</P>
<P>
<SUP>2</SUP> Downgraded this single study, with concurrent limitations in study design (non-blinded outcome assessment, leading to potential detection bias).</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2011-03-22 07:49:44 +1000" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2015-04-06 19:15:43 +1000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2015-04-06 19:00:10 +1000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Comparison of frequency of meningitis with antibiotic prophylaxis versus no antibiotic</NAME>
<DICH_OUTCOME CHI2="1.1822302112284864" CI_END="1.5907550077840855" CI_START="0.25144344811798536" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="0.6324436135088907" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.20160329909328256" LOG_CI_START="-0.5995596763416292" LOG_EFFECT_SIZE="-0.19897818862417338" METHOD="MH" MODIFIED="2015-04-06 19:00:10 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7572693764716876" P_Q="0.5755051858145204" P_Z="0.3302751046785194" Q="0.31355791061360305" RANDOM="NO" SCALE="788.7" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="109" TOTAL_2="99" WEIGHT="100.0" Z="0.9735599256835127">
<NAME>Frequency of meningitis by subgroup</NAME>
<GROUP_LABEL_1>Antibiotic prophylaxis</GROUP_LABEL_1>
<GROUP_LABEL_2>No antibiotic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ab prophylaxis</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no ab</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.9188342705715312" CI_END="2.15121158420465" CI_START="0.08969020829575332" DF="2" EFFECT_SIZE="0.4392523364485982" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="0.33268312788324955" LOG_CI_START="-1.0472549673822338" LOG_EFFECT_SIZE="-0.35728591974949214" NO="1" P_CHI2="0.6316517384754524" P_Z="0.31014111091705654" STUDIES="3" TAU2="0.0" TOTAL_1="51" TOTAL_2="41" WEIGHT="41.28644735271888" Z="1.0149260134130142">
<NAME>CSF leakage (rhinorrhoea or otorrhoea)</NAME>
<DICH_DATA CI_END="3.9411293615047898" CI_START="0.005356799964719067" EFFECT_SIZE="0.1452991452991453" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.5956206901474258" LOG_CI_START="-2.2710945708832013" LOG_EFFECT_SIZE="-0.8377369403678877" ORDER="40945" O_E="0.0" SE="1.6839227347987933" STUDY_ID="STD-Demetriades-1992" TOTAL_1="19" TOTAL_2="9" VAR="2.835595776772247" WEIGHT="16.929372687855523"/>
<DICH_DATA CI_END="11.028202310693292" CI_START="0.09067661000654373" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="1.0425047245730008" LOG_CI_START="-1.0425047245730008" LOG_EFFECT_SIZE="0.0" ORDER="40947" O_E="0.0" SE="1.224744871391589" STUDY_ID="STD-Eftekhar-2004" TOTAL_1="6" TOTAL_2="6" VAR="1.5" WEIGHT="11.575639444687535"/>
<DICH_DATA CI_END="8.243132894662011" CI_START="0.01248112699144645" EFFECT_SIZE="0.32075471698113206" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9160923015364291" LOG_CI_START="-1.9037461979814594" LOG_EFFECT_SIZE="-0.49382694822251516" ORDER="40946" O_E="0.0" SE="1.6563870930424989" STUDY_ID="STD-Klastersky-1976" TOTAL_1="26" TOTAL_2="26" VAR="2.74361820199778" WEIGHT="12.781435220175823"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.408578044309304" CI_START="0.24507142213370764" DF="0" EFFECT_SIZE="0.7682926829268293" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.3817607231701695" LOG_CI_START="-0.6107073290304394" LOG_EFFECT_SIZE="-0.11447330293013498" NO="2" P_CHI2="1.0" P_Z="0.6511735039628798" STUDIES="2" TAU2="0.0" TOTAL_1="53" TOTAL_2="53" WEIGHT="58.71355264728111" Z="0.45213254056274055">
<NAME>No CSF leakage</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="40948" O_E="0.0" SE="0.0" STUDY_ID="STD-Demetriades-1992" TOTAL_1="6" TOTAL_2="3" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.408578044309304" CI_START="0.24507142213370764" EFFECT_SIZE="0.7682926829268293" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.3817607231701695" LOG_CI_START="-0.6107073290304394" LOG_EFFECT_SIZE="-0.11447330293013498" ORDER="40949" O_E="0.0" SE="0.5829806466587287" STUDY_ID="STD-Eftekhar-2004" TOTAL_1="47" TOTAL_2="50" VAR="0.3398664343786295" WEIGHT="58.71355264728111"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.01.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>Presence of CSF leakage not specified</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="40950" O_E="0.0" SE="0.0" STUDY_ID="STD-Ignelzi-1975a" TOTAL_1="5" TOTAL_2="5" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.242467406803081" CI_END="1.6064247714436979" CI_START="0.29228167258451315" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="0.6852215109574117" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.20586039243850607" LOG_CI_START="-0.5341984160656115" LOG_EFFECT_SIZE="-0.1641690118135527" METHOD="MH" MODIFIED="2015-03-27 06:50:56 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5372815002854334" P_Q="1.0" P_Z="0.384537100031932" Q="0.0" RANDOM="NO" SCALE="381.8" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="109" TOTAL_2="99" WEIGHT="100.0" Z="0.8695669772040928">
<NAME>Frequency of meningitis</NAME>
<GROUP_LABEL_1>Antibiotic prophylaxis</GROUP_LABEL_1>
<GROUP_LABEL_2>No antibiotic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ab prophylaxis</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no ab</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.242467406803081" CI_END="1.6064247714436979" CI_START="0.29228167258451315" DF="2" EFFECT_SIZE="0.6852215109574117" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="0.20586039243850607" LOG_CI_START="-0.5341984160656115" LOG_EFFECT_SIZE="-0.1641690118135527" NO="1" P_CHI2="0.5372815002854334" P_Z="0.384537100031932" STUDIES="4" TAU2="0.0" TOTAL_1="109" TOTAL_2="99" WEIGHT="100.0" Z="0.8695669772040928">
<NAME>Frequency of meningitis</NAME>
<DICH_DATA CI_END="3.976916324477006" CI_START="0.005682328761390108" EFFECT_SIZE="0.1503267973856209" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.5995464533947799" LOG_CI_START="-2.2454736429947917" LOG_EFFECT_SIZE="-0.8229635948000059" ORDER="40951" O_E="0.0" SE="1.6711788876958404" STUDY_ID="STD-Demetriades-1992" TOTAL_1="25" TOTAL_2="12" VAR="2.7928388746803066" WEIGHT="15.203779140880572"/>
<DICH_DATA CI_END="2.1798058175024217" CI_START="0.33357088902090953" EFFECT_SIZE="0.8527131782945736" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" LOG_CI_END="0.33841780730032145" LOG_CI_START="-0.4768118575823693" LOG_EFFECT_SIZE="-0.06919702514102394" ORDER="40952" O_E="0.0" SE="0.47886994060401666" STUDY_ID="STD-Eftekhar-2004" TOTAL_1="53" TOTAL_2="56" VAR="0.22931642001409444" WEIGHT="73.385105578001"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="40953" O_E="0.0" SE="0.0" STUDY_ID="STD-Ignelzi-1975a" TOTAL_1="5" TOTAL_2="5" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="8.243132894662011" CI_START="0.01248112699144645" EFFECT_SIZE="0.32075471698113206" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9160923015364291" LOG_CI_START="-1.9037461979814594" LOG_EFFECT_SIZE="-0.49382694822251516" ORDER="40954" O_E="0.0" SE="1.6563870930424989" STUDY_ID="STD-Klastersky-1976" TOTAL_1="26" TOTAL_2="26" VAR="2.74361820199778" WEIGHT="11.411115281118427"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2015-03-27 06:56:23 +1000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Comparison of all-cause mortality with antibiotic prophylaxis versus no antibiotic</NAME>
<DICH_OUTCOME CHI2="0.2097685043771809" CI_END="6.9514118613127955" CI_START="0.40702661835691945" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="1.682084915429755" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.8420730206052331" LOG_CI_START="-0.39037718825016743" LOG_EFFECT_SIZE="0.22584791617753283" METHOD="MH" MODIFIED="2015-03-27 06:52:18 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.646948921471743" P_Q="1.0" P_Z="0.4725530393068156" Q="0.0" RANDOM="NO" SCALE="636.5166342029972" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="109" TOTAL_2="99" WEIGHT="100.00000000000001" Z="0.7183313021667402">
<NAME>All-cause mortality</NAME>
<GROUP_LABEL_1>Antibiotic prophylaxis</GROUP_LABEL_1>
<GROUP_LABEL_2>No antibiotic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ab prophylaxis</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no ab</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="40955" O_E="0.0" SE="0.0" STUDY_ID="STD-Demetriades-1992" TOTAL_1="25" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="81.01418950953843" CI_START="0.12866478739703358" EFFECT_SIZE="3.2285714285714286" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9085610915452214" LOG_CI_START="-0.8905402932789334" LOG_EFFECT_SIZE="0.509010399133144" ORDER="40956" O_E="0.0" SE="1.6442060092210264" STUDY_ID="STD-Eftekhar-2004" TOTAL_1="53" TOTAL_2="56" VAR="2.7034134007585338" WEIGHT="15.70590265792199"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="40957" O_E="0.0" SE="0.0" STUDY_ID="STD-Ignelzi-1975a" TOTAL_1="5" TOTAL_2="5" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="6.9527990387577985" CI_START="0.2794654387599383" EFFECT_SIZE="1.393939393939394" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.8421596768730522" LOG_CI_START="-0.5536718932656788" LOG_EFFECT_SIZE="0.14424389180368663" ORDER="40958" O_E="0.0" SE="0.8199183737771973" STUDY_ID="STD-Klastersky-1976" TOTAL_1="26" TOTAL_2="26" VAR="0.672266139657444" WEIGHT="84.29409734207802"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2015-03-27 06:56:46 +1000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Comparison of meningitis related mortality with antibiotic prophylaxis versus no antibiotic</NAME>
<DICH_OUTCOME CHI2="0.9788882742318338" CI_END="7.398335427700007" CI_START="0.14278200931529172" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="1.02778849864917" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.8691340175845157" LOG_CI_START="-0.8453265106782829" LOG_EFFECT_SIZE="0.011903753453116374" METHOD="MH" MODIFIED="2015-03-27 06:53:02 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.32247364561750436" P_Q="1.0" P_Z="0.9782869433050938" Q="0.0" RANDOM="NO" SCALE="592.5238691415933" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="109" TOTAL_2="99" WEIGHT="100.0" Z="0.027216640645081277">
<NAME>Meningitis-related mortality</NAME>
<GROUP_LABEL_1>Antibiotic prophylaxis</GROUP_LABEL_1>
<GROUP_LABEL_2>No antibiotic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ab prophylaxis</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no ab</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="40959" O_E="0.0" SE="0.0" STUDY_ID="STD-Demetriades-1992" TOTAL_1="25" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="81.01418950953843" CI_START="0.12866478739703358" EFFECT_SIZE="3.2285714285714286" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9085610915452214" LOG_CI_START="-0.8905402932789334" LOG_EFFECT_SIZE="0.509010399133144" ORDER="40960" O_E="0.0" SE="1.6442060092210264" STUDY_ID="STD-Eftekhar-2004" TOTAL_1="53" TOTAL_2="56" VAR="2.7034134007585338" WEIGHT="24.31493631802393"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="40961" O_E="0.0" SE="0.0" STUDY_ID="STD-Ignelzi-1975a" TOTAL_1="5" TOTAL_2="5" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="8.243132894662011" CI_START="0.01248112699144645" EFFECT_SIZE="0.32075471698113206" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9160923015364291" LOG_CI_START="-1.9037461979814594" LOG_EFFECT_SIZE="-0.49382694822251516" ORDER="40962" O_E="0.0" SE="1.6563870930424989" STUDY_ID="STD-Klastersky-1976" TOTAL_1="26" TOTAL_2="26" VAR="2.74361820199778" WEIGHT="75.68506368197608"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2015-04-06 19:15:43 +1000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Comparison of the need for surgical correction in patients with CSF leakage with antibiotic prophylaxis versus no antibiotic</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2015-04-06 19:15:43 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.4441605731096927" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="53" TOTAL_2="56" WEIGHT="0.0" Z="0.0">
<NAME>Need for surgical correction in patients with CSF leakage</NAME>
<GROUP_LABEL_1>Antibiotic prophylaxis</GROUP_LABEL_1>
<GROUP_LABEL_2>No antibiotic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ab prophylaxis</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no ab</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="40963" O_E="0.0" SE="0.0" STUDY_ID="STD-Eftekhar-2004" TOTAL_1="53" TOTAL_2="56" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2015-04-06 19:09:30 +1000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Comparison of frequency of non-CNS infection with antibiotic prophylaxis versus no antibiotic</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.4641003597081403" CI_START="0.14906432555452204" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.6060606060606061" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="0.3916583921205713" LOG_CI_START="-0.8266262805483839" LOG_EFFECT_SIZE="-0.21748394421390627" METHOD="MH" MODIFIED="2015-04-06 19:09:30 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.4840697629844085" Q="0.0" RANDOM="NO" SCALE="646.72" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="26" TOTAL_2="26" WEIGHT="0.0" Z="0.6997719128176254">
<NAME>Non-CNS infection</NAME>
<GROUP_LABEL_1>Antibiotic prophylaxis</GROUP_LABEL_1>
<GROUP_LABEL_2>No antibiotic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ab prophylaxis</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no ab</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.4641003597081403" CI_START="0.14906432555452204" DF="0" EFFECT_SIZE="0.6060606060606061" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="6" I2="0.0" ID="CMP-005.01.01" LOG_CI_END="0.3916583921205713" LOG_CI_START="-0.8266262805483839" LOG_EFFECT_SIZE="-0.21748394421390627" NO="1" P_CHI2="1.0" P_Z="0.4840697629844085" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="26" WEIGHT="0.0" Z="0.6997719128176254">
<NAME>CSF leakage (rhinorrhoea or otorrhoea)</NAME>
<DICH_DATA CI_END="2.464100359708141" CI_START="0.14906432555452204" EFFECT_SIZE="0.6060606060606061" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.39165839212057135" LOG_CI_START="-0.8266262805483839" LOG_EFFECT_SIZE="-0.21748394421390627" ORDER="40964" O_E="0.0" SE="0.7156264473321344" STUDY_ID="STD-Klastersky-1976" TOTAL_1="26" TOTAL_2="26" VAR="0.5121212121212122" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2015-03-27 08:25:58 +1000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2015-03-27 08:25:58 +1000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAZIAAAK2CAYAAABkVxpHAABXRUlEQVR42u2dC9RV097/TyolpELk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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2015-02-26 19:46:33 +1000" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAm8AAAEACAMAAADSomGoAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2015-02-26 19:46:33 +1000" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAVkAAAIXCAIAAAC5KroNAABMA0lEQVR42u2dCVgVV9L3UVwQUFBZ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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2015-02-26 03:39:02 +1000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2015-02-26 03:37:05 +1000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2009-09-24 16:15:58 +1000" MODIFIED_BY="[Empty name]">Previous searches</TITLE>
<APPENDIX_BODY MODIFIED="2015-02-26 03:37:05 +1000" MODIFIED_BY="[Empty name]">
<P>For our previous update, we searched the Cochrane Central Register of Controlled Trials (CENTRAL 2011, Issue 1) (accessed 17 February 2011), which contains the Cochrane Acute Respiratory Infections (ARI) Group's Specialised Register, MEDLINE (2005 to February, Week 3 2011), EMBASE (2005 to February 2011) and LILACS (2005 to February 2011).</P>
<P>Prior to this we searched the Cochrane Register of Controlled Trials (CENTRAL 2005, Issue 3), which contains the Cochrane Acute Respiratory Infections (ARI) Group's Specialised Register, MEDLINE (1966 to September 2005), EMBASE (1974 to June 2005) and LILACS (1982 to September 2005). We also performed an electronic search of meeting proceedings of the American Association of Neurological Surgeons (1997 to September 2005) and handsearched the abstracts of meeting proceedings of the European Association of Neurosurgical Societies (1995, 1999 and 2003).</P>
<P>The search strategy for MEDLINE and CENTRAL is given below. It was combined with all three stages of the optimal trial search strategy (<LINK REF="REF-Dickersin-1994" TYPE="REFERENCE">Dickersin 1994</LINK>). The search strategy was modified for EMBASE and LILACS.</P>
<P>1. exp Anti Bacterial Agents/<BR/>2. antibiotic$.tw<BR/>3. antimicrob$.tw<BR/>4. antibacter$.tw<BR/>5. Bacteriocid$.tw<BR/>6. Antimycobacter$.tw<BR/>7. or/1-6<BR/>8. exp Central Nervous System Infections/<BR/>9. exp Infection/<BR/>10. infect$.tw<BR/>11. meningit$.tw<BR/>12. or/8-11<BR/>13. exp Brain Injuries/<BR/>14. brain and injur$.tw<BR/>15. brain and traum$.tw<BR/>16. brain and contusio$.tw<BR/>17. brain and laceratio$.tw<BR/>18. exp Craniocerebral Trauma/<BR/>19. cranial and injur$.tw<BR/>20. cranial and traum$.tw<BR/>21. craniocerebral and injur$.tw<BR/>22. craniocerebral and traum$.tw<BR/>23. exp Head Injuries, Penetrating/<BR/>24. head and injur$.tw<BR/>25. head and traum$.tw<BR/>26. exp Skull Fractures/<BR/>27. skull and fractur$.tw<BR/>28. brain and fractur$.tw<BR/>29. temporal and fractur$.tw<BR/>30. basilar and fractur$.tw<BR/>31. Battle$.tw<BR/>32. frontobasilar and fractur$.tw<BR/>33. basal and skull and fractur$.tw<BR/>34. base and skull and fractur$.tw<BR/>35. Cerebrospinal fluid/<BR/>36. cranio$ and traum$.tw<BR/>37. Subdural effusion/<BR/>38. hygroma.tw<BR/>39. cerebrospinal and fluid and fistul$.tw<BR/>40. CSF$ and fistul$.tw<BR/>41. cerebrospinal and fluid and leakag$.tw<BR/>42. CSF$ and fistul$.tw<BR/>43. Cerebrospinal Fluid Rhinorrhea/<BR/>44. Cerebrospinal Fluid Otorrheas/<BR/>45. or/13-44<BR/>46. 7 and 12 and 45<BR/>47. limit 46 to human</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2014-06-19 13:10:51 +1000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2014-06-19 11:00:05 +1000" MODIFIED_BY="[Empty name]">MEDLINE (Ovid) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-06-19 11:00:28 +1000" MODIFIED_BY="[Empty name]">
<P>1 exp Anti-Bacterial Agents/<BR/>2 antibiotic*.tw,nm.<BR/>3 antimicrob*.tw,nm.<BR/>4 antibacter*.tw,nm.<BR/>5 bacteriocid*.tw,nm.<BR/>6 antimycobacter*.tw,nm.<BR/>7 or/1-6<BR/>8 exp Central Nervous System Infections/<BR/>9 exp Infection/<BR/>10 infect*.tw.<BR/>11 exp Meningitis/<BR/>12 meningit*.tw.<BR/>13 or/8-12<BR/>14 exp Brain Injuries/<BR/>15 (brain adj3 (injur* or traum* or contusio* or laceratio*)).tw.<BR/>16 Craniocerebral Trauma/<BR/>17 ((craniocerebral or cranial) adj3 (injur* or traum*)).tw.<BR/>18 Head Injuries, Penetrating/<BR/>19 (head adj3 (injur* or traum*)).tw.<BR/>20 exp Skull Fractures/<BR/>21 (fractur* adj3 (skull or brain or temporal or basilar or frontobasilar or basal or base)).tw.<BR/>22 (battl* adj2 sign*).tw.<BR/>23 Cerebrospinal Fluid/<BR/>24 (cranio* adj3 traum*).tw.<BR/>25 Subdural Effusion/<BR/>26 hygroma*.tw.<BR/>27 ((csf or cerebrospinal fluid) and (fistula* or leakage*)).tw.<BR/>28 cerebrospinal fluid otorrhea/ or cerebrospinal fluid rhinorrhea/<BR/>29 exp Intracranial Hemorrhage, Traumatic/<BR/>30 or/14-29<BR/>31 7 and 13 and 30</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2015-02-26 03:39:02 +1000" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2009-09-24 16:15:34 +1000" MODIFIED_BY="[Empty name]">Embase.com search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2015-02-26 03:39:02 +1000" MODIFIED_BY="[Empty name]">
<P>The following search strategy was combined with filters for randomised trials and observational studies</P>
<TABLE COLS="1" ROWS="1">
<TR>
<TD>
<P>#1.28 #1.3 AND #1.27</P>
<P>#1.27 #1.9 AND #1.26 </P>
<P>#1.26 #1.10 OR #1.11 OR #1.12 OR #1.13 OR #1.14 OR #1.15 OR #1.16 OR #1.17 OR #1.18 OR #1.19 OR #1.20 OR #1.21 OR #1.22 OR #1.23 OR #1.24 OR #1.25<BR/>#1.25 ('traumatic intracranial' NEAR/2 (haemorrhage* OR hemorrhage* OR hematoma* OR haematoma*)):ab,ti </P>
<P>#1.24 'cerebrospinal fluid otorrhea'/de OR 'cerebrospinal fluid rhinorrhea'/de AND [embase]/lim </P>
<P>#1.23 ((csf OR 'cerebrospinal fluid') NEAR/5 (fistula* OR leakage*)):ab,ti AND [embase]/lim </P>
<P>#1.22 hygroma*:ab,ti AND [embase]/lim </P>
<P>#1.21 'subdural effusion'/de </P>
<P>#1.20 (cranio* NEAR/3 traum*):ab,ti AND [embase]/lim </P>
<P>#1.19 'cerebrospinal fluid'/de AND [embase]/lim </P>
<P>#1.18 (battl* NEAR/2 sign*):ab,ti AND [embase]/lim </P>
<P>#1.17 (fractur* NEAR/3 (skull OR brain OR temporal OR basilar OR frontobasilar OR basal OR base)):ab,ti AND [embase]/lim </P>
<P>#1.16 'skull base fracture'/de AND [embase]/lim </P>
<P>#1.15 (head NEAR/3 (injur* OR traum*)):ab,ti AND [embase]/lim </P>
<P>#1.14 (penetrat* NEAR/3 head*):ab,ti AND [embase]/lim </P>
<P>#1.13 ((craniocerebral OR cranial) NEAR/3 (injur* OR traum*)):ab,ti AND [embase]/lim </P>
<P>#1.12 'head injury'/de AND [embase]/lim </P>
<P>#1.11 (brain NEAR/3 (injur* OR traum* OR contusio* OR laceratio*)):ab,ti AND [embase]/lim </P>
<P>#1.10 'brain injury'/exp AND [embase]/lim </P>
<P>#1.9 #1.4 OR #1.5 OR #1.6 OR #1.7 OR #1.8 </P>
<P>#1.8 meningit*:ab,ti AND [embase]/lim</P>
<P>#1.7 'meningitis'/exp AND [embase]/lim</P>
<P>#1.6 infect*:ab,ti AND [embase]/lim </P>
<P>#1.5 'infection'/de AND [embase]/lim </P>
<P>#1.4 'central nervous system infection'/exp AND [embase]/lim </P>
<P>#1.3 #1.1 OR #1.2 </P>
<P>#1.2 antibiotic*:ab,ti OR antimicrob*:ab,ti OR antibacter*:ab,ti OR bacteriocid*:ab,ti OR antimycobacter*:ab,ti AND [embase]/lim </P>
<P>#1.1 'antibiotic agent'/exp AND [embase]/lim</P>
</TD>
</TR>
</TABLE>
<P>Filter for randomised trials<BR/>
</P>
<TABLE COLS="2" ROWS="1">
<TR>
<TD COLSPAN="2">
<P>#2.8 #2.3 NOT #2.7</P>
<P>#2.7 #2.4 NOT #2.6 </P>
<P>#2.6 #2.4 AND #2.5 </P>
<P>#2.5 'human'/de AND [embase]/lim </P>
<P>#2.4 'animal'/de OR 'nonhuman'/de OR 'animal experiment'/de AND [embase]/lim </P>
<P>#2.3 #2.1 OR #2.2 </P>
<P>#2.2 random*:ab,ti OR placebo*:ab,ti OR crossover*:ab,ti OR 'cross over':ab,ti OR allocat*:ab,ti OR trial:ti OR (doubl* NEXT/1 blind*):ab,ti AND [embase]/lim </P>
<P>#2.1 'randomized controlled trial'/exp OR 'single blind procedure'/exp OR 'double blind procedure'/exp OR 'crossover procedure'/exp AND [embase]/lim</P>
</TD>
</TR>
</TABLE>
<P>Filter for finding observational studies (based on SIGN observational filter)</P>
<P>'case control':ab,ti OR 'case-control':ab,ti OR (cohort NEAR/1 (study OR studies OR analys*)):ab,ti OR ('follow up' NEAR/1 (study OR studies)):ab,ti OR (observation* NEAR/1 (study OR studies)):ab,ti OR longitudinal:ab,ti OR retrospective:ab,ti OR 'cross sectional':ab,ti AND [embase]/lim<BR/>'case control study'/exp OR 'cohort analysis'/exp OR 'follow up'/de OR 'observational study'/de OR 'longitudinal study'/de OR 'retrospective study'/de OR 'cross-sectional study'/de AND [embase]/lim<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2014-06-19 13:10:45 +1000" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2009-09-24 16:15:47 +1000" MODIFIED_BY="[Empty name]">LILACS search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-06-19 11:53:38 +1000" MODIFIED_BY="[Empty name]">
<TABLE COLS="2" ROWS="2">
<TR>
<TH VALIGN="TOP">
<P>Database:</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>LILACS</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Search on:</P>
</TD>
<TD VALIGN="TOP">
<P>tw:((mh:"Anti-Bacterial Agents" OR antibacterianos OR antibiotic* OR mh:d27.505.954.122.085* OR antibióticos OR antimicrob* OR antibacter* OR bacteriocid* OR antimycobacter*) AND (mh:"Central Nervous System Infections" OR mh:c01.395* OR mh:c10.228.228* OR mh:infection OR mh:c01.539* OR infect* OR infección OR infecção OR mh:meningitis OR mh:c10.228.228.507* OR mh:c10.228.566* OR meningit*) AND (mh:"Brain Injuries" OR mh:c10.228.140.199* OR mh:c10.900.300.087* OR mh:c26.260.118* OR mh:c26.915.300.200* OR "Traumatismos Encefálicos" OR "brain injuries" OR "brain injury" OR "brain trauma" OR "brain contusion" OR "brain contusions" OR "brain laceration" OR "brain lacerations" OR "Lesión Cerebral" OR "Lesiones Encefálicas" OR "Traumatismo Cerebral" OR "Traumatismos Cerebrales" OR "Contusión Encefálica" OR "Lesiones Traumáticas del Encéfalo" OR "Lesiones Encefálicas Traumáticas" OR "Laceraciones del Encéfalo" OR "Laceraciones Encefálicas" OR "Traumatismo Encefálico" OR "Lesiones del Encéfalo Traumáticas" OR "Lesão Cerebral" OR "Lesões Encefálicas" OR "Traumatismo Cerebral" OR "Traumatismos Cerebrais" OR "Contusão Encefálica" OR "Lesões Encefálicas Traumáticas" OR "Lacerações Encefálicas" OR "Traumatismo do Encéfalo" OR "Lesão Encefálica Traumática" OR mh:"Craniocerebral Trauma" OR "Traumatismos Craneocerebrales" OR "Traumatismos Craniocerebrais" OR "head injury" OR "head injuries" OR "head trauma" OR "Trauma Craneocerebral" OR "Lesión Craneocerebral" OR "Trauma Craniano" OR mh:"Head Injuries, Penetrating" OR "Traumatismos Penetrantes de la Cabeza" OR "Traumatismos Cranianos Penetrantes" OR mh:"Skull Fractures" OR mh:c10.900.300.918* OR mh:c26.260.836* OR mh:c26.404.750* OR mh:c26.915.300.745* OR "Fracturas Craneales" OR "Fraturas Cranianas" OR "skull fracture" OR "basilar fracture" "frontobasilar fracture" OR "basal fracture" OR "basilar skull fracture" OR "battle sign" OR "battle's sign" OR mh:"Cerebrospinal Fluid" OR "Líquido Cefalorraquídeo" OR "Líquido Cefalorraquidiano" OR mh:"Subdural Effusion" OR "Efusión Subdural" OR "Derrame Subdural" OR hygroma* OR mh:"Cerebrospinal Fluid Otorrhea" OR "Otorrea de Líquido Cefalorraquídeo" OR "Otorreia de Líquido Cefalorraquidiano" OR "Cerebrospinal Otorrhea" OR "Otorrea del Líquido Cerebroespinal" OR "Otorrea Cefalorraquídea" OR "Otorreia Liquórica" OR mh:"Intracranial Hemorrhage, Traumatic" OR "Traumatic Intracranial Hemorrhage" OR mh:c10.228.140.300.535.450* OR mh:c10.900.300.837* OR mh:c14.907.253.573.400* OR mh:c26.260.616* OR mh:c26.915.300.490* OR "Hemorragia Traumática Intracraneal")) AND (instance:"regional") AND ( db:("LILACS") AND year_cluster:("2012" OR "2011" OR "2013" OR "2014"))</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;4 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;5 studies included in qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;29 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;2289 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;2289 records after duplicates removed&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;962 records identified through database searching&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;1365 additional records identified through other sources&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;2281 records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;23 full-text articles excluded, with reasons&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>